Document:

License Agreement dated June 11,2003 between the Registrant and Glaxo Group Ltd

 EXHIBIT 10.2 
  
  
 [GLAXO HEADER]

  
 June     , 2003 
  
 POZEN Inc. 
 1414 Raleigh Road, Suite 400 
 Chapel Hill, NC 27517 
  
     Subject:     Initial Development Plan and Strategic Plan 
  
 We refer to that certain Product Development and Commercialization Agreement,
dated as of the date hereof (the “Agreement”), by and between POZEN INC., a Delaware corporation (“POZEN”), and Glaxo Group Ltd., a corporation organized under the laws of England, doing
business as GlaxoSmithKline (“GSK”). Capitalized terms used but not otherwise defined herein will have the meanings assigned to such terms in the Agreement. In connection with the execution and delivery of the Agreement and the
consideration set forth therein, POZEN and GSK hereby enter into this Letter Agreement and agree as follows: 
  
 1. Delivery of Initial Development Plan and Strategic Plan. The Initial Development Plan is attached hereto as Exhibit A and hereby delivered and agreed by GSK and POZEN. The Strategic Plan is attached
hereto as Exhibit B and hereby delivered and agreed by GSK and POZEN. 
  
 2. Termination. The term of this Letter Agreement is the Term of the Agreement. 
  
 3. Miscellaneous. This Letter Agreement and any disputes arising hereunder will be governed by and construed in accordance with Article 13 of the Agreement. The terms of this Letter Agreement and the Exhibits
hereto will be modified or amended only in accordance with Section 14.5 of the Agreement. This Letter will be assigned or transferred only in connection with an assignment of the Agreement and will be binding upon, and inure to the benefit of, the
successors and assigns of the parties hereto, in each case as provided in Section 14.2 of the Agreement. This Letter Agreement may be executed in one or more counterparts, including facsimile counterparts, each of which will constitute an original,
but all of which taken together will form one and the same agreement. 
  
 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE EXHIBITS TO THIS AGREEMENT THAT ARE MARKED WITH ASTERISKS AND BRACKETS ([***]). COMPLETE COPIES OF THESE EXHIBITS, INCLUDING THE REDACTED PORTIONS, HAVE BEEN
SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 [REMAINDER OF PAGE INTENTIONALLY
LEFT BLANK] 

 The parties hereto set forth their agreement with the terms and provisions of this Letter Agreement by
signing below. 
  

			
	GLAXO GROUP LTD., D/B/A
GLAXOSMITHKLINE
		
	 By:
	 	 
		
	 Name:
	 	 
		
	 Title:
	 	 

  
 Accepted and Agreed as of June
11, 2003: 
  

			
	POZEN Inc.
		
	 By:
	 	 
		
	 Name:
	 	 
		
	 Title:
	 	 

 Exhibit A 
  

Initial Development Plan 
  
 MT400 is a combination tablet containing [***] mg sumatriptan ([***] mg sumatriptan succinate) and [***] mg naproxen sodium. The goal of this plan is to register the
product for the acute treatment of migraine. 
  
 The Development Timeline
(including the overall plan and timings for completion of work) is shown in Figure 1. This timeline and plan is split into various elements of activity. The POZEN Development Activities (for which POZEN is responsible) are detailed in Section 1, and
the GSK Development Activities (for which GSK is responsible) are detailed in Section 2. 
  
 The Pozen Development Timeline is the timeline associated with POZEN Development Activities and incorporated as part of the Development Timeline shown in Figure 1. The Formulation Development Timeline is the timeline
associated with the GSK Development Activities and incorporated as part of the Development Timeline shown in Figure 1. 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE EXHIBIT THAT ARE MARKED WITH ASTERISKS AND
BRACKETS ([***]). A COMPLETE COPY OF THIS EXHIBIT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

1 

 Figure 1 
  

[***] [Entire page redacted] 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 2 

 1 POZEN DEVELOPMENT ACTIVITIES 
  
 1.1 [***] Study 
  
 A [***] study in [***] to assess any potential [***] will be performed at [***] (or equivalent) [***]. Effects of selected [***] on the following parameters will be
evaluated: [***]; and calculated [***]. Effects of [***] on the above parameters may be evaluated. Doses selected should achieve [***] for MT400. This study is to be completed before the [***], unless the FDA allows otherwise. 
  
 1.2 [***] Study 
  
 Study Design 
  
 The [***] study will be an [***] study to compare [***], and to investigate the [***] male and female [***] compared to [***]. 
  
 This will be a [***] study in approximately [***] may be employed). 
  
 Objectives 
  
 1. [***]. 
  
 2. [***]. 
  
 3. [***]. 
  
 4. [***]. 
  
 Primary Endpoints 
  
 [***] 
  
 Secondary endpoints 
  
 1. [***] and other [***] parameters of interest 
  
 2. [***] parameters[***] 
  
 Population and Enrollment 

 
 The study will be conducted in approximately [***] male and female [***]. The goal is to
have [***]. 
  
 Route/Dosage/Treatment Duration 
  
 All doses will be administered as a [***] following an [***]. There will be a [***].

  
 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE
AGREEMENT THAT ARE MARKED WITH ASTERISKS AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 1.3 [***] Study 
  
 Design 
  
 The [***] study will be an [***] study comparing [***] male and female [***]. 
  
 Objective 
  
 To compare the [***].

  
 Primary Endpoints 
  
 [***] 
  
 Secondary endpoints 
  
 [***] 
  
 Population and Enrollment 
  
 The study will be conducted in
[***] male and female [***] to obtain [***]. 
  
 Route/Dosage/Treatment
Duration 
  
 All doses will be administered as [***] following an [***]. The
subjects will receive [***]. There will be [***]. 
  
 1.4 [***] Study

  
 Design 
  
 The [***] study will be an [***] study to investigate the effect of [***] male and female
subjects. 
  
 Objective 
  
 To compare the [***]. 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 4 

 Primary Endpoints 
  
 [***] 
  
 Secondary endpoints 
  
 [***] 
  
 Population and Enrollment 
  
 The study will be conducted in [***] male and female [***]. 
  
 Route/Dosage/Treatment Duration 
  
 [***] doses will be administered with [***]. There will be a [***]. 
  
 1.5 Study Design of [***] 
  
 [***] male and female [***] will constitute the [***]. Eligible subjects will receive [***].
Following screening, subjects will have up [***]. 
  
 Clinical endpoints in the
[***] 
  
 1. The primary, clinical endpoint in the [***] 
  
 2. The key secondary clinical endpoints are: 
  

	 	•	Percentage of [***] 

  

	 	•	Percentage of [***] 

  
 3. Additional secondary endpoints are: 
  

	 	•	Percentage of [***] 

  

	 	•	Percentage of [***] 

  

	 	•	Percentage of [***] 

  

	 	•	Presence or absence of [***] 

  

	 	•	The percentage of [***] 

  

	 	•	Percentage of [***] 

  

	 	•	Use of [***] 

  

	 	•	[***] 

  

	 	•	[***] 

  

	 	•	Percentage of [***] 

  

	 	•	Percentage of [***] 

  

	 	•	[***] 

  

	 	•	[***] 

  

	 	•	Data pertaining to [***] 

  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 5 

 Study Population 
  
 The study population will consist of males or females [***]. Subjects must have [***] and must not have [***]. Subjects must have [***]. 
  
 Study Length 
  
 Subjects will be [***]. Subjects will [***]. 
  
 Measurements and Evaluations 
  
 Subjects will [***] will have the option [***] The key primary and secondary endpoints will be measured by [***] will be measured by [***] Additional endpoints will use
[***] 
  
 Assessments will be made every [***] 
  
 [***] Calculation 
  
 The primary objective is to show that [***]. This objective will be met by [***]. The [***] of primary interest are [***]. To meet the
primary objective [***] necessary for the primary endpoint, [***] for the key secondary endpoints [***]. 
  
 [***] Using the same test strategy, [***] to detect [***]. Because we are using [***] we must consider [***] This is achieved by [***] Assume that the [***] Adding the [***] for the overall [***]. 
  
 Number of [***] 
  
 For each [***] study, assuming approximate [***] approximately [***] ensure that at least [***] in order to complete the study in accordance
with the timeline. 
  
 1.6 [***] Study 
  
 An [***] study will be conducted to provide [***] data [***]  
  
 The submission to the FDA will include [***] 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 6 

 1.7 Regulatory Responsibility 
  
 FDA guidance will be sought [***] or if necessary with [***] for the design [***] The filing of all regulatory documents necessary to
conduct clinical development activities will be the responsibility of Pozen (IND and any supplements) as provided in Section 3.5(a) of the Agreement. Pozen will file the NDA seeking approval of MT400 for the treatment of migraine as provided in
Section 3.5(a) of the Agreement. 
  
 2 GSK DEVELOPMENT ACTIVITIES

  
 2.1 Formulation 
  
 GSK will develop [***] formulation containing [***] Relevant studies to the formulation work
will include [***] 
  
 2.2 Manufacture 
  
 GSK will be responsible for manufacture of clinical supply of MT400 as well as [***] and
placebo. These responsibilities include: 
  

	1.	CTM for [***] 

  

	2.	Packaging [***] 

  

	3.	Any required analytical testing 

  
 When launched GSK will be responsible for commercial supply of MT400, including all packaging requirements. 
  
 2.3 Regulatory Responsibility 
  
 GSK will compile the CMC regulatory documentation and provide it to Pozen for the purpose of the IND and NDA submissions to the agreed clinical development program
required for product registration. The sponsorship and ownership of the IND and NDA will be transferred to GSK after approval of MT400 as provided in Section 3.5(a) of the Agreement. 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 7 

 Exhibit B 
  

MT400 STRATEGIC PLAN AND KEY COMMERCIAL OBJECTIVES 
  
 POSITIONING 
  
 Key Commercial Objective: GSK will position MT400 as [***]. 
  
 MT400 is projected to launch in [***]. Based on the most recent competitive intelligence, there is little evidence [***]. Currently, there is also no evidence to indicate
that [***]. 
  
 MT400 is expected to deliver [***], a key efficacy measure for
[***]. It is also expected to show [***]. This combination of product attributes should enable MT400 to realize [***]. The fact that [***] will also enable GSK [***]. Hence, physicians would prescribe MT400 [***]. 
  
 MT400, would meet the top need [***] and could potentially [***]. 
  
 [***] COVERAGE 
  
 Key Commercial Objective: GSK will incorporate MT400 into the portfolio for [***]. 
  
 A key factor in market success for any new migraine therapy is [***]. For MT400 to be
successful, [***]. Preliminary feedback would indicate that obtaining this coverage is possible. 
  
 [***] 
  
 Key Commercial Objective:
GSK will position MT400 as[***]. 
  
 Based on market research estimates
[***]. This research also showed that [***]. 
  
 Price is currently
assumed to be [***]. This strategy will be tested in market research to ensure that [***]. Pack sizes are also assumed to be [***]. This is considered a better value proposition to patients and physicians. This would further allow fast adoption
[***] and rapid uptake by physicians. 
  

	•	GSK plans to commence naming strategies, including marketing research [***]. 

  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE EXHIBIT THAT ARE MARKED WITH ASTERISKS AND
BRACKETS ([***]). A COMPLETE COPY OF THIS EXHIBIT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

1 

	•	Starting [***] prior to launch [***], GSK will commence initial marketing strategies [***]: 

  

	 	•	Data and discussions at [***] 

  

	 	•	Public Relations Activities 

  

	 	•	Publications 

  
 PROMOTION 
  
 Key
Commercial Objective: GSK will support MT400 with a [***]. 
  
 A&P
Spending for 2006-7 
  
 [***] is estimated as follows: 
  

							
	 [***]
	  	[***]	  	 [***]
	  	 
				
	 A&P Spending*
	  	        [***]	  	         [***]
	  	 
				
	 *[***]
	  	 	  	 	  	 

  
 Detailing Levels 
  
 GSK currently plans to support MT400 with [***]. The majority of which will be [***].

  

															
								
	 [***]
	  	 [***]
	  	[***]	 	[***]	  	 	  	 	  	 	  	 
								
	 Details
	  	         [***]
	  	        [***]	 	        [***]	  	 	  	 	  	 	  	 
								
	 	  	 	  	 	 	 	  	 	  	 	  	 	  	 

  
 [***] 
  
 [***] 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 2License Agreement dated June 30, 2003 between the Registrant and Nycomed Danmark

 EXHIBIT 10.3 
  
 POZEN INC./NYCOMED DANMARK APS 
  
 LICENSE AGREEMENT 
  
 TABLE OF CONTENTS 
  

							
	 	  	 	  	 	  	PAGE

	1.	  	DEFINITIONS	  	1
	2.	  	MANAGEMENT OF COLLABORATION	  	7
	 	  	2.1	  	Collaboration Management Committee	  	7
	 	  	2.2	  	Functions and Powers of the CMC	  	7
	 	  	2.3	  	Limitations of CMC Powers	  	8
	 	  	2.4	  	CMC Actions	  	8
	 	  	2.5	  	CMC Meetings	  	8
	3.	  	PRODUCT DEVELOPMENT	  	8
	 	  	3.1	  	Development Program	  	8
	 	  	3.2	  	Performance of Duties	  	9
	4.	  	REGULATORY MATTERS	  	9
	 	  	4.1	  	Distribution of Tasks Regarding Regulatory Approval of the Initial Product	  	9
	 	  	4.2	  	Additional Requirements for Marketing Approval	  	10
	 	  	4.3	  	Distribution of Tasks for Other Products	  	11
	 	  	4.4	  	Maintenance of Marketing Approvals	  	11
	 	  	4.5	  	Meetings and Correspondence	  	12
	 	  	4.6	  	Adverse Events Reporting	  	12
	 	  	4.7	  	[***]	  	13
	5.	  	MANUFACTURE AND SUPPLY	  	13
	6.	  	COMMERCIALIZATION	  	13
	 	  	6.1	  	Principles of Commercialization	  	13
	 	  	6.2	  	Marketing Plan	  	13
	 	  	6.3	  	Branding; Trademarks; Trade Dress; Logos	  	14
	 	  	6.4	  	Establishment of Units and Minimum Royalties	  	15
	7.	  	DILIGENCE	  	15
	 	  	7.1	  	General Diligence Obligations	  	15
	 	  	7.2	  	Minimum Launch Diligence Obligations	  	16
	 	  	7.3	  	Minimum Commercialization Diligence Obligations	  	16
	 	  	7.4	  	Diligence Limitations	  	16
	 	  	7.5	  	Lack of Diligence	  	17
	 	  	7.6	  	[***]	  	17
	8.	  	LICENSES AND OTHER RIGHTS	  	17

  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION 
  
 i 
  

							
	 	  	8.1	  	License Grants to License	  	17
	 	  	8.2	  	Negative Covenants	  	18
	 	  	8.3	  	License Grants to POZEN	  	19
	9.	  	COMPENSATION	  	19
	 	  	9.1	  	License Fees	  	19
	 	  	9.2	  	Milestones	  	19
	 	  	9.3	  	Royalties	  	20
	 	  	9.4	  	Reports; Payment Method; Currency	  	20
	 	  	9.5	  	Blocked Currency	  	21
	 	  	9.6	  	Taxes	  	21
	 	  	9.7	  	Audit Rights; Adjustments	  	21
	10.	  	INTELLECTUAL PROPERTY	  	22
	 	  	10.1	  	Licensee’s Obligation to Inform	  	22
	 	  	10.2	  	POZEN’s Obligation to Inform	  	22
	 	  	10.3	  	Ownership	  	23
	 	  	10.4	  	Patent Filing, Prosecution and Maintenance	  	23
	 	  	10.5	  	Enforcement Rights	  	24
	 	  	10.6	  	Defense and Settlement of Third Party Claims	  	26
	 	  	10.7	  	Indemnification	  	26
	11.	  	REPRESENTATIONS AND WARRANTIES	  	26
	 	  	11.1	  	Mutual Representations and Warranties	  	26
	 	  	11.2	  	POZEN Representations and Warranties	  	27
	 	  	11.3	  	Limitation of Warranty	  	28
	 	  	11.4	  	Performance of Affiliates	  	28
	12.	  	INDEMNIFICATION	  	28
	 	  	12.1	  	Indemnification by Licensee	  	28
	 	  	12.2	  	Indemnification by POZEN	  	29
	 	  	12.3	  	Indemnification Procedures	  	29
	 	  	12.4	  	Insurance	  	30
	13.	  	LIMITATION OF LIABILITY	  	30
	14.	  	CONFIDENTIALITY, PUBLICATIONS, PUBLICITY	  	30
	 	  	14.1	  	Confidential Information	  	30
	 	  	14.2	  	Treatment of Confidential Information	  	31
	 	  	14.3	  	Access	  	31
	 	  	14.4	  	Permitted Disclosures	  	31
	 	  	14.5	  	Return of Confidential Information	  	31
	 	  	14.6	  	Confidentiality of the Agreement Terms	  	32
	 	  	14.7	  	Publications	  	32
	 	  	14.8	  	Publicity	  	32
	15.	  	TERM AND TERMINATION	  	33

  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 ii 

							
	 	  	15.1	  	Term of the Agreement	  	33
	 	  	15.2	  	Termination for Material Breach	  	33
	 	  	15.3	  	Termination for MAA Failure	  	33
	 	  	15.4	  	Termination for MAA Withdrawal	  	33
	 	  	15.5	  	Termination for Bankruptcy	  	34
	 	  	15.6	  	Termination of Supply Agreement	  	34
	16.	  	CONSEQUENCES OF TERMINATION	  	34
	 	  	16.1	  	General	  	34
	 	  	16.2	  	Termination Prior to Expiration by POZEN	  	34
	 	  	16.3	  	Licenses Upon Expiration	  	35
	 	  	16.4	  	Survival	  	35
	17.	  	DISPUTE RESOLUTION	  	35
	18.	  	MISCELLANEOUS	  	36
	 	  	18.1	  	Patents and Trademarks	  	36
	 	  	18.2	  	Further Assurances	  	36
	 	  	18.3	  	Assignment	  	36
	 	  	18.4	  	Independent Contractors	  	36
	 	  	18.5	  	Waiver	  	37
	 	  	18.6	  	Amendment	  	37
	 	  	18.7	  	Severability	  	37
	 	  	18.8	  	Notice	  	37

  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 iii 

 LICENSE AGREEMENT 
  
 THIS LICENSE
AGREEMENT(the “Agreement”) is made and entered into as of June 30, 2003 (the “Effective Date”), by and between POZEN INC., a Delaware corporation (“POZEN”),
with a business address of 1414 Raleigh Road, Suite 400, Chapel Hill, NC 27517, and NYCOMEDDANMARK APS, a Danish corporation (“Licensee” or “Nycomed”), located at
Langebjerg 1, DK-4000 Roskilde, Denmark. POZEN and Licensee are referred to in this Agreement individually as a “Party” and collectively as “Parties.” 
  
 RECITALS 
  
 A. Licensee is a pharmaceutical company possessing substantial expertise in the development and marketing of pharmaceutical products; 
  
 B. POZEN is a pharmaceutical development company currently
specializing in the development of products for migraine therapy; 
  
 C. POZEN and Licensee desire to collaborate on the development of POZEN’s MT 100TM product, and to
have Licensee market, promote, sell and distribute such product within Denmark, Norway, Sweden and Finland so as to maximize its commercial potential. 
  
 AGREEMENT 
  
 In consideration of the mutual covenants contained in this Agreement and other good and valuable consideration, the receipt and sufficiency of which is
hereby acknowledged, the Parties agree as follows: 
  
 1. DEFINITIONS

  
 The capitalized terms used in this Agreement will have the
meanings given to them in this Section 1 and throughout this Agreement. 
  
 1.1 “Affiliate” means a corporation or other business entity which, directly or indirectly, through one or more intermediaries, controls, is controlled by or is under common control with a
Party. For purposes of this definition only, “control” and, with corresponding meanings, the terms “controlled by” and “under common control with” means (a) the possession, 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 1 

 directly or indirectly, of the power to direct the management or policies of a legal entity, whether through the
ownership of voting securities or by contract relating to voting rights or corporate governance, or (b) the ownership, directly or indirectly, of more than 50% of the voting securities or other ownership interest of a legal entity; provided,
however, that if local law restricts foreign ownership, control will be established by direct or indirect ownership of the maximum ownership percentage that may, under such local law, be owned by foreign interests. 
  
 1.2 “CMC” has the meaning set forth in Section 2.1 of
this Agreement. 
  
 1.3 “Competing
Product” means any generic pharmaceutical product containing all and only the same active ingredients as a Product. 
  
 1.4 “Confidential Information” has the meaning set forth in Section 14.1 of this Agreement. 
  
 1.5 “Control” means, with respect to a Party and any
Patent, Know-How, other intellectual property right, or Regulatory Approval, (a) that such Party owns or has a license to use such Patent, Know-How, intellectual property right or Regulatory Approval, and (b) has the ability to grant the other Party
access, a license or a sublicense (as applicable) or right to use such Patent, Know-How, or intellectual property right, or the right to reference such Regulatory Approval during the Term without violating the rights of any Third Party and without
obligation to make any payments to a Third Party as a result of such grant of access, license or sublicense, or right of reference, or the exercise thereof by the other Party. 
  
 1.6 “Cost of Manufacture” means, with respect to any product, the actual fully allocated cost of
manufacturing such product determined in accordance with U.S. generally accepted and consistently applied accounting principles, which consists of the direct and indirect cost of any raw materials, packaging materials and labor (including benefits)
utilized in such manufacturing (including formulation, filling, finishing, quality control and stability testing, labeling and packaging, as applicable). 
  
 1.7 “Development Program” has the meaning set forth in Section 3.1 of this Agreement. 
  
 1.8 “DMF” means a drug master file to be maintained
with the applicable regulatory authorities in each country of the Territory. 
  
 1.9 “DSM” means DSM Pharmaceuticals Inc., formerly known as Catalytica Pharmaceuticals, Inc. 
  
 1.10 “DSM Agreement” means the agreement by and between POZEN and DSM dated January 17, 2001. 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 2 

 1.11 “Due Diligence Issue” means an issue listed in Exhibit A to this Agreement
that was identified by Licensee as a potential hurdle to obtaining approval of the POZEN MAA. 
  
 1.12 “Field” means the treatment of human diseases or conditions by means of a prescription pharmaceutical product. 
  
 1.13 “Improvement” means any invention, discovery or Know-How, whether or not patentable, relating
to the Product and developed solely or jointly by POZEN, Licensee, their Affiliates or their Third Party contractors after the Effective Date in the course of performing a Development Program or commercializing a Product. Any general patent or
patent application which relates both to the Product as well as to other active substances shall not be included in the definition of Improvement. 
  
 1.14 “Initial Indication” means the acute treatment of migraine attacks with or without aura. 
  
 1.15 “Initial Product” means an oral formulation of
Product containing [***] naproxen sodium and [***] metoclopramide hydrochloride developed by POZEN as of the Effective Date under the POZEN MAA for the Initial Indication, that conforms to the specifications set forth on Exhibit 2 of the Supply
Agreement. 
  
 1.16 “Know-How” means
information, results and data of any type whatsoever, in any tangible or intangible form whatsoever, including databases, practices, methods, techniques, specifications, formulations, formulae, knowledge, know-how, skill, experience, test data
including pharmacological, medicinal chemistry, biological, chemical, biochemical, toxicological and clinical test data, analytical and quality control data, stability data, studies and procedures, and manufacturing process and development
information, results and data. 
  
 1.17 “Licensed
Technology” means the POZEN Know-How, POZEN Patents, and any Improvements. 
  
 1.18 “Licensee Trademarks” means any trademarks or trade names used or registered by Licensee to identify the company as of the Effective Date or during the Term. 
  
 1.19 “MAA” means a Marketing Authorization
Application submitted to the appropriate regulatory body in a European country (including Norway) for the purposes of obtaining approval for the marketing of a prescription pharmaceutical product in such country. 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 3 

 1.20 “Marketing Approval” means approval of an MAA in a country of the Territory.

  
 1.21 “Marketing Plan” has the meaning
set forth in subsection 6.2.1 of this Agreement. 
  
 1.22
“MCA” means the United Kingdom Medicines Control Agency, or any successor agency thereof. 
  
 1.23 “Minimum Royalty Amount” has the meaning set forth in Exhibit F attached to this Agreement and hereby incorporated in this
Agreement by reference. 
  
 1.24 “MRP”
means the Mutual Recognition Procedure for obtaining approval of MAAs in each country of the Territory. 
  
 1.25 “Net Sales” means the gross amount invoiced by Licensee or its Affiliates for sale or other commercial disposition of a
Product to a Third Party, less the following deductions: 
  
 (a) Discounts and allowances allowed and taken for returns or rejections (provided such amounts have been formally designated as such in accordance with the internal accounting procedures, consistently applied, of Licensee and its
Affiliates), and wholesaler chargebacks allowed and taken in amounts customary in the trade; 
  
 (b) Import, export, excise, sales or use taxes, value added taxes, and other taxes, tariffs or duties levied, absorbed or directly imposed and properly allocable to particular sales of Products (in any event
excluding taxes on the income of Licensee and its Affiliates); 
  
 (c) Freight, postage, shipping, insurance, and packaging costs and other outbound transportation charges prepaid or allowed to the extent included as part of the invoiced amount; 
  
 (d) Amounts allowed or credited for [***] rebates; 

 
 (e) The amounts of trade and cash discounts actually allowed on
account of the purchase of Products; 
  
 (f) Allowances,
adjustments, reimbursements, discounts and rebates actually granted to Third Parties, including, but not limited to, rebates given to health care organizations or other Third Parties who bought or paid for a Product; 
  
 (g) [***] 
  
 (h) [***] 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 4 

 Notwithstanding the foregoing, if: (i) a Product is sold together with other goods, whether with a separate price for
such Product (unless such separate price is the same as the price for such Product when not sold together with other goods) or without a separate price for such Product, (ii) the consideration exchanged for a Product includes any non-cash
consideration, or (iii) a Product is transferred for purposes of resale, in any manner other than as an invoiced sale, then, in each case the Net Sales applicable to the quantity of such Product included in any such transaction will be deemed to be
the average Net Sales for such quantity of such Product for all transactions of such Product (other than those described in the preceding clauses (i)-(iii), inclusive) made in the relevant country during the last full calendar quarter prior to such
transaction (or, if the Product was not commercially available during the last full calendar quarter preceding such transaction, during the current quarter). 
  
 In the event that Products are sold or otherwise disposed of to a Third Party other than on arm’s length terms and are subsequently sold or otherwise disposed of by
such Third Party on arm’s length terms, then Net Sales will be calculated based upon the first such arm’s length sale or disposition. “Net Sales” excludes (a) the transfer of reasonable and customary quantities of free samples of
Product to physicians for professional use, other than for subsequent resale, (b) the transfer of Product as clinical trial materials, other than for subsequent resale, and (c) the transfer of Product to any regulatory agency in a country in the
Territory for use by such agency in connection with securing Regulatory Approval for such Product in such country. 
  
 1.26 “Patent” means patents, letters patent, applications for patents, provisional applications for patents, and any patents
issuing therefrom (including any divisions, continuations, continued prosecution applications and continuations-in-part thereof), reexamination certificates, reissue patents, patent extensions, patent term restorations, supplementary protection
certificates, and any equivalents, substitutions, confirmations, registrations, revalidations, additions, continuations in part and divisions thereof. 
  
 1.27 “POZEN Know-How” means (a) any non-public or confidential sections of the POZEN MAA, and (b) any other non-public or
confidential Know-How Controlled by POZEN during the Term that is necessary for the performance of pre-clinical or clinical development, for the filing of Regulatory Approvals in the Territory, or the commercialization, marketing or manufacture of a
Product. 
  
 1.28 “POZEN MAA” means MAA
#PL19852/0001 submitted to the MCA on October 8, 2002, or any successor application thereof, to obtain approval for the marketing of the Initial Product in the Initial Indication in the United Kingdom. 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 5 

 1.29 “POZEN Patents” means EP#1014961, any Patents issuing therefrom, and any
other Patents Controlled by POZEN during the Term that would be infringed, in the absence of a license, by the manufacture, use, sale, offer for sale or importation of a Product in the Territory. 
  
 1.30 “POZEN Trademarks” means any trademarks or trade
names used or registered by POZEN to identify the company as of the Effective Date or during the Term. 
  
 1.31 “Product” means any presentation and/or dosage strength of a formulation combining naproxen sodium and metoclopramide
hydrochloride for any indication. 
  
 1.32 “Product
Promotional Materials” means all sales representative training materials and all written, printed, graphic, electronic, audio or video matter, including but not limited to journal advertisements, sales visual aids, leave-behind items,
formulary binders, reprints, direct mail, direct-to-consumer advertising, internet postings, media broadcast advertisements, and sales reminder aids (for example, note pads, pens and other such items) intended for use or used by a Party in
connection with any promotion of a Product. 
  
 1.33
“Product Trademarks” means any trademarks, trade dress, logos, slogans, and designs, whether or not registered in the Territory, used to identify or promote a Product in the Territory, but excluding any Licensee Trademarks or
POZEN Trademarks. 
  
 1.34 “Regulatory
Approval” means any approvals (including price reimbursement approvals) and any master files, DMFs, establishment licenses, registrations or authorizations of any national or local regulatory agency, department, bureau or other governmental
entity, necessary for the manufacture, use, storage, importation, export, transport, distribution or sale of a Product in the Field (including the approval of an MAA). 
  
 1.35 “Supply Agreement” has the meaning set forth in Section 5 of this Agreement. 
  
 1.36 “Supply Price” means any payments made by POZEN
to DSM, or DSM’s successor or assignee, for the purchase of Product, as well as the [***] actually paid or utilized by POZEN in respect of such purchase of Product [***]. 
  
 1.37 “Term” has the meaning set forth in Section 15.1 of this Agreement. 
  
 1.38 “Territory” means Denmark, Norway, Sweden and
Finland. 
  
 1.39 “Third Party” means any
individual or entity other than POZEN, Licensee and their respective Affiliates. 
  
 1.40 “UK Target Date” means [***]. 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 6 

 1.41 “Unit” means, with respect to the Initial Product, a single tablet of the
Initial Product, and, with respect to other Products, such unit as the Parties establish pursuant to Section 6.4 of this Agreement. 
  
 1.42 “Valid Claim” means any claim of a Patent which has not (a) been held permanently unenforceable, unpatentable or invalid by a
decision of a court or governmental agency of competent jurisdiction, which decision is not appealable or is not appealed within the time allowed for an appeal, (b) been admitted to be invalid or unenforceable generally through reissue, disclaimer
or otherwise, (c) expired or been canceled and/or (d) been intentionally abandoned. 
  
 1.43 “Withdraw” means, with respect to an MAA, to permanently remove such MAA from consideration by the regulatory authorities in a country without undertaking remedial measures to address
deficiencies in such MAA raised by such regulatory authorities. 
  
 2. MANAGEMENT OF COLLABORATION 
  
 2.1 Collaboration Management Committee. The Parties will manage the commercialization and development of Products by Licensee through a collaboration management committee (the “CMC”). Prior to the first meeting of the CMC,
each Party will designate an equal number of representatives, but no fewer than two of its employees as its representatives on the CMC. Each Party will designate at least one representative with expertise in the technical, regulatory and scientific
aspects of pharmaceutical product development and at least one representative with expertise in the commercial aspects of pharmaceutical product sales and marketing. Each Party will select one of the representatives to the CMC as such Party’s
primary contact person for communication between the Parties relating to any aspects of this Agreement (each such representative, a “Collaboration Manager”). An alternate member designated by a Party may serve on the CMC temporarily
in the absence of a permanent member, and may replace such permanent member on a permanent basis, if necessary. Each Party will bear its own costs of participation in the CMC. 
  
 2.2 Functions and Powers of the CMC. The CMC will perform the following functions: (a) monitor the progress of, and
provide input to, POZEN’s efforts in seeking approval of the POZEN MAA and in the preparation and filing of Regulatory Approvals in the countries of the Territory through the MRP, (b) review and comment on each initial and updated Marketing
Plan; (c) oversee and monitor the clinical development of a Product in the Territory pursuant to any Development Program; (d) oversee and monitor the development and scale-up of the manufacturing process for a Product pursuant to any Development
Program; (e) oversee and provide input to Licensee’s efforts in the preparation and filing of Regulatory Approvals and other matters pertaining to regulatory 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 7 

 affairs relating to a Product; (f) serve as a forum for communication between the Parties for the activities performed
pursuant to each Marketing Plan and Development Program; and (g) address and attempt to resolve conflicts or disputes that may arise during the course of performing this Agreement. 
  
 2.3 Limitations of CMC Powers. The CMC will have only such powers as are specifically delegated to it in this
Agreement, and will have no power to amend this Agreement or waive a Party’s rights or obligations under this Agreement. Delegation of powers to the CMC will not relieve either Party from its obligations under this Agreement. 
  
 2.4 CMC Actions. No business will be transacted at any meeting of the
CMC unless at least one member from each Party is present. Actions by the CMC will be taken only with the unanimous approval of all representatives of both Parties. If the CMC is unable to reach unanimity on any matter within 15 days of the first
vote at which no unanimous decision was reached on such matter, then each Party may refer such matter to the Chief Executive Officers of the Parties for resolution. If a matter is so referred, then such Chief Executive Officers (or a member of the
senior management designated by the Chief Executive Officer who is not a member of the CMC) will, within 15 days of referral, discuss such matter in good faith. If such discussions do not result in a mutually acceptable resolution within 10 days of
such meeting, then either Party may initiate dispute resolution procedures pursuant to Section 17 of this Agreement, to the extent the subject of such dispute is alleged to constitute a breach of contract by the other Party. 
  
 2.5 CMC Meetings. The CMC will hold meetings at such times and places
as will be determined by the Collaboration Managers, but in no event will such meetings be held in person or by teleconference or video conference less frequently than: (a) [***] during the period commencing on the Effective Date and ending upon
[***] of receipt of Marketing Approval for a Product in the last country in the Territory; (b) after such period, [***] during the following [***] period; and (c) after such [***] period, as [***] for the duration of the term of the Agreement. The
first meeting of the CMC will take place within [***] after the Effective Date. The Collaboration Managers will establish an agenda for each such meeting and will designate representatives of the Parties who will have management responsibility for
the issues on the agenda for such meeting. 
  
 3. PRODUCT DEVELOPMENT 
  
 3.1 Development
Program. Licensee will [***] undertake a program to: (1) develop [***], in the Territory, (2) develop Products for indications other than the Initial Indication, and (3) conduct post-approval studies with Products (each such program, a
“Development Program”). Any Development Program, including study designs or protocols included in such Development Program, will be subject to review and approval by POZEN [***]. 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 8 

 3.2 Performance of Studies. If Licensee desires to use a Third Party to perform a study in
connection with a Development Program, Licensee will notify POZEN of such desire and will accompany such notice with a description of the study objectives and a binding estimate and associated proposal provided to Licensee by a reputable Third Party
contract research organization of the cost of performing such study. POZEN will have [***] following receipt of such notice to reply with a binding offer to perform such study and to provide reasonable evidence to Licensee that POZEN has appropriate
experience developing pharmaceutical products in the Territory (whether directly or indirectly through its contractors). If POZEN provides such an offer during such [***] period, then: (a) [***]% [***] then Nycomed will engage POZEN for the
performance of the applicable study, or (b) [***]% [***] then Nycomed will be free to engage the Third Party that provided the applicable estimate to perform such study. In any event, if POZEN does not provide an offer within the [***] period
described in this Section 3.2, then Nycomed will be free to engage any Third Party to perform the applicable study. 
  
 4. REGULATORY MATTERS 
  
 4.1 Distribution of Tasks Regarding Regulatory Approval of the Initial Product. 
  
 4.1.1 POZEN will: (a) furnish Licensee with a copy of the POZEN MAA (excluding any portion thereof that POZEN is not
entitled to disclose to Licensee) promptly after the Effective Date, and other documentation to the extent reasonably available to POZEN, that POZEN deems reasonably necessary for the MRP for the Initial Product in each country of the Territory; (b)
prepare the MRP for the Initial Product together with the regulatory authorities in the United Kingdom (including without limitation scheduling the MRP with each of the countries in the Territory), and file an MAA for the Initial Product in all
countries of the Territory; (c) provide supplementary documentation relating to the Initial Product if so requested by the regulatory authorities in the United Kingdom and each country in the Territory, to the extent reasonably available to POZEN as
of the date of request; (d) answer any questions relating to the Initial Product from the regulatory authorities in the United Kingdom and each country in the Territory; (e) transfer to Licensee any Marketing Approvals for the Initial Product
obtained in the Territory; and (f) submit to the MCA any post-Marketing Approval changes prepared by Licensee pursuant to clause (c) of subsection 4.1.2 below. 
  

4.1.2 Licensee will: (a) make translations of the MAAs and other documentation, if so requested by the regulatory authorities in the Territory;
(b) after the transfer of the respective Marketing Approval, be the first point of contact with the regulatory authorities 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 9 

 in each country in the Territory and will use commercially reasonable efforts to maintain such Marketing Approval during
the Term; (c) provide to POZEN documentation for post-Marketing Approval changes for submission to the MCA where necessary, including but not limited to new formulations, line extensions, new packaging, new dosage strengths, and new indications; and
(d) subject to the diligence requirements set forth in Section 7 of this Agreement, perform the actions required to obtain pricing or reimbursement approval of a Product in each country of the Territory. For the avoidance of doubt, but subject to
the diligence requirements set forth in Section 7 of this Agreement, Nycomed grants no warranties for the obtainment of reimbursement. Licensee further agrees that it will not amend any Marketing Approval in the Territory without POZEN’s prior
written consent. Each Party shall cooperate in good faith with the other Party’s efforts to obtain supplementary protection certificates for the Product in Europe. In the case of Licensee, such cooperation will include, without limitation,
promptly providing POZEN with a complete copy of each MAA filed, and Marketing Approval obtained, in the Territory (to the extent POZEN does not already possess a complete copy of such MAA or Marketing Approval). 
  
 4.1.3 Licensee will bear all costs and expenses incurred by the
Parties in connection with performing their obligations pursuant to this Section 4.1, excluding any costs and expenses incurred by POZEN in connection with securing Marketing Approval for the Initial Product in the United Kingdom; provided,
however, that in relation to maintenance of the Marketing Approval described in clause (c) of subsection 4.1.2, the provisions regarding the distribution of costs set out in Section 4.4 will apply. 
  
 4.2 Additional Requirements for Marketing Approval. 
  
 4.2.1 If the regulatory authorities in the United Kingdom or any
country in the Territory require additional data or information to be submitted by POZEN as a condition to approving the POZEN MAA or granting Marketing Approval for the Initial Product in the Territory, POZEN will inform Licensee thereof without
delay. Subject to subsection 4.2.2 below, POZEN will, at its expense, conduct such studies as are necessary to satisfy the requests of the applicable regulatory authorities. 
  
 4.2.2 If, in POZEN’s judgment, either (a) [***] by a regulatory authority in the United Kingdom or any country
in the Territory as a condition to granting Marketing Approval for the Initial Product in such country, or (b) the [***] by any such regulatory authority, [***] POZEN may Withdraw the applicable MAA or other filing and will inform Licensee of such
decision without delay. In such event, POZEN will [***] set forth in Section [***], and this Agreement will terminate in whole or in part as set forth in Section 15.4. 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 10 

 4.3 Distribution of Tasks for Other Products. 
  
 4.3.1 With respect to Products to be developed pursuant to a
Development Program, the Parties will establish in such Development Program the distribution of tasks with respect to Regulatory Approvals of such Products in the Territory. Licensee shall at its discretion decide on the level of expenses of the
Development Program. Licensee will bear all costs and expenses incurred by the Parties in connection with performing each Development Program. 
  
 4.3.2 With respect to Products developed by POZEN and covered by the rights and licenses granted to Licensee under this Agreement, the Parties will
establish the distribution of tasks with respect to Regulatory Approvals of such Products in the Territory. Licensee will bear all costs and expenses incurred by the Parties in connection with obtaining Regulatory Approvals of such Products in the
Territory. 
  
 4.4 Maintenance of Marketing Approvals.
POZEN will, throughout the Term, provide reasonable technical and scientific support to enable Licensee to maintain Marketing Approvals in the Territory. Licensee will reimburse POZEN for any internal costs (at then-standard FTE rates) only for
services outside the ordinary maintenance of the Marketing Approvals. Licensee will reimburse POZEN for out-of-pocket expenses incurred by POZEN in connection with such provision of support under the terms set forth in this Section 4.4 (such FTE
rates and costs to be agreed upon in writing by the Parties prior to initiation of any such support). Under this provision the “ordinary maintenance” shall mean provision of information already available with POZEN and updates caused by
changes in legislation and guidelines applicable also for European countries outside the Territory. 
  
 4.4.1 If (a) the regulatory authorities in one or more countries in the Territory require changes or additions to data, specifications, or other
information set forth in an approved MAA in order to maintain Marketing Approval for a Product in such country or countries (including, by way of example, changes to the specifications of a Product or to the process or facilities used to manufacture
a Product, additional clinical trials relating to a Product, or other changes to the labeling, handling, or manufacture of a Product), and (b) no regulatory authority in a European country outside the Territory in which POZEN or its licensee has
obtained Marketing Approval requires such changes or additions from POZEN or POZEN’s licensee in order to maintain such Marketing Approval, then, provided such changes or additions are commercially reasonable, Licensee will implement such
changes or additions at its own cost and expense in the Territory upon POZEN’s prior written approval to do so, or will reimburse POZEN for all costs and expenses incurred by POZEN to effect such changes in the United Kingdom if necessary and
in each country in the Territory requiring such changes. If such changes or additions are not commercially reasonable and Nycomed does not wish to implement such changes, POZEN has the right to terminate the agreement for the country of which such

  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 11 

 change has been requested. If one or more regulatory authorities in a European country outside the Territory in which
POZEN or its licensees have obtained Marketing Approval of the Product require such changes or additions [***] set out in clause [***] below shall [***], as applicable. 
  
 4.4.2 If (a) the regulatory authorities in one or more countries in the Territory require changes or additions to
data, specifications, or other information set forth in an approved MAA in order to maintain Marketing Approval for a Product in such country or countries (including, by way of example, changes to the specifications of a Product or to the process or
facilities used to manufacture a Product, additional clinical trials relating to a Product, or other changes to the labeling, handling, or manufacture of a Product), and (b) the regulatory authorities in one or more European countries outside the
Territory in which POZEN or its licensee has obtained Marketing Approval require such changes or additions in order to maintain such Marketing Approval, then Licensee will reimburse POZEN for a percentage of all costs and expenses incurred by POZEN
to effect such changes, which percentage will be calculated by [***]. 
  
 4.5 Meetings and Correspondence. 
  
 4.5.1
To the extent either Party receives any written or oral communications relating to a Product from any regulatory authority in the Territory, such Party will promptly inform the other Party thereof (including by providing a copy of any written
communication or a written account of any oral communication), but in no event later than 5 business days after receipt of such communication. 
  
 4.5.2 Each Party will promptly notify the other Party, and provide such other Party with a copy, of any correspondence or other reports or
complaints submitted to or received by the first Party from any regulatory authority in the Territory or from any other Third Party claiming that any Product Promotional Materials are inconsistent with a Product’s labeling or are otherwise in
violation of applicable law or regulation. 
  
 4.5.3 Each
Party will provide the other Party with a copy of any documents or reports filed with any regulatory authority in the Territory during the Term with respect to a Product. 
  
 4.6 Adverse Events Reporting. Nycomed will provide POZEN with prompt written notice of any serious adverse drug event
or reaction reports received by Nycomed with respect to Products in the Territory, including copies of any such written reports where available. POZEN will provide Nycomed with prompt written notice of any serious adverse drug event or reaction
reports received by POZEN with respect to Products in any jurisdiction outside the Territory where POZEN is, at such time, developing or marketing Products, including copies of any such written reports where available. Nycomed will be 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 12 

 responsible for complying with adverse drug event reporting requirements in the Territory with respect to Products and
will copy POZEN on all correspondence with regulatory authorities in the Territory regarding the same. POZEN will be responsible for complying with adverse drug event reporting requirements in jurisdictions outside the Territory where POZEN is, at
such time, developing or marketing Products and will copy Nycomed on all correspondence between POZEN and the regulatory authorities in such jurisdictions regarding serious adverse drug events or reactions. POZEN will have the right to redact such
correspondence to remove information proprietary to POZEN as applicable. 
  
 4.7 [***]. Subject to the terms and conditions set forth in this Agreement, [***] of Products in one or more countries in the Territory. 
  
 5. MANUFACTURE AND SUPPLY 
  
 As of the Effective Date, Licensee and POZEN have entered into an agreement (the “Supply Agreement”)
regarding the manufacture and supply of the Initial Product by POZEN to Licensee, a copy of which is attached as Exhibit G to this Agreement. 
  
 6. COMMERCIALIZATION 
  
 6.1 Principles of Commercialization. Licensee will be solely responsible for the commercialization of the Products in the Field in all countries of
the Territory during the Term as set forth in the applicable Marketing Plan. Licensee will bear all expenses incurred in connection with the preparation and execution of the Marketing Plan. 
  
 6.2 Marketing Plan. 
  
 6.2.1 Licensee will commercialize each Product in the Territory under
this Agreement pursuant to a rolling multi-year plan and budget (the “Marketing Plan”). Licensee will prepare each Marketing Plan according to Licensee’s marketing planning process, and will include in each Marketing Plan
comprehensive education, market development, marketing, sales and supply strategies, including an overall budget for anticipated marketing, promotion and sales efforts in the period covered by such Marketing Plan. Each Marketing Plan will identify
commercial milestones and the criteria by which the Parties will evaluate achievement of these milestones. Each Marketing Plan will describe the Product’s positioning and specify toward which target populations and distribution channels
Licensee will devote its promotional efforts, the personnel and other resources to be devoted by Licensee to such efforts, as well as market and sales forecasts and related operating expenses, for the applicable Product in the Territory, and budgets
for projected commercialization expenses and sales and marketing expenses. Each Marketing Plan will include the general strategy and operating guidelines for the commercialization of the applicable Product. 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 13 

 6.2.2 The initial Marketing Plan for each Product, including the Initial Product, will be prepared
by Licensee in accordance with its procedures and in due time before commercial launch of such Product. A preliminary Marketing Plan of each Product will be prepared no later than 12 months prior to the expected date of receipt of Marketing Approval
for such Product in any country in the Territory. Such preliminary Marketing Plan may be adjusted in good faith and in a commercially reasonable manner during Licensee’s regular budget process. Licensee will update each Marketing Plan at least
once every year. 
  
 6.2.3 Licensee will submit the final
draft of each initial and updated Marketing Plan to the CMC [***] in accordance with Licensee’s corporate planning cycle. The CMC will have 30 working days [***] on such draft to Licensee, and Licensee will [***] prior to finalization and
implementation of such plan. 
  
 6.3 Branding; Trademarks;
Trade Dress; Logos. 
  
 6.3.1 At the request of POZEN,
Licensee will, to the extent permitted by law and customary to local trade and practice, include one or more POZEN Trademarks designated by POZEN in relevant information disclosed publicly by Licensee relating to this Agreement or a Product, in the
form of press releases, technical publications, regulatory filings, pharmaceutical product packaging, and seminar and conference posters regarding this Agreement or a Product. 
  
 6.3.2 [***] will select all Product Trademarks for use on or in connection with the Products, subject to [***] prior
approval. POZEN will be the sole owner of the Product Trademarks. POZEN will be responsible for the filing, prosecution, maintenance and defense of all registrations of the Product Trademarks, and will be responsible for the payment of any costs
relating to filing, prosecution, maintenance and defense of the Product Trademarks in the Territory. Upon expiry of this Agreement in a country in the Territory, POZEN will grant to Licensee an exclusive license unlimited in time to the Product
Trademarks in such country, for which Licensee will pay to POZEN a royalty of 3% of Net Sales in such country. 
  
 6.3.3 Subject to the provisions of subsection 6.3.1 above and the use of Licensee Trademarks as required by applicable laws and regulations,
Licensee will market, promote, sell and distribute the Products under the Product Trademarks only, unless the Parties agree otherwise in writing. 
  
 6.3.4 POZEN will have the right to review and approve any Product Promotional Materials and any labels or packaging materials prepared by or for
Licensee that bear one or more Product Trademarks or POZEN Trademarks in order to confirm that such trademarks are being used correctly and in accordance with the terms of this Agreement. In 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 14 

 addition, at the request of POZEN, Licensee will not use any claims in any Product Promotional Materials that, in
POZEN’s reasonable discretion, are inconsistent with the label approved in the applicable country in the Territory or that, if used, would materially impair the development, sale, promotion, or other commercialization efforts of POZEN or its
other licensees outside the Territory with respect to the applicable Product. If POZEN receives a draft of Product Promotional Materials, labels or packaging under this subsection 6.3.4, then POZEN will use commercially reasonably efforts to
acknowledge such receipt within 5 business days and will, in any event, provide comments to Licensee within 10 business days from receipt of such draft. If POZEN does not provide Licensee with any comments within such 10-day period, then any such
draft Product Promotional Materials submitted for review will be deemed approved by POZEN. If POZEN provides Licensee with substantive comments to any such draft after such 10-day period has expired that are necessary to ensure that the Product
Trademarks or POZEN Trademarks are used properly or that the claims in such materials are consistent with the label approved in the applicable country in the Territory, then Licensee will incorporate such comments in the relevant Product Promotional
Materials. 
  
 6.3.5 Licensee acknowledges POZEN’s
exclusive right, title and interest in and to the Product Trademarks and POZEN Trademarks and acknowledges that nothing in this Agreement will be construed to accord to Licensee any rights in the Product Trademarks or POZEN Trademarks except as
expressly provided in this Agreement (including, without limitation, the license upon expiry granted under subsection 6.3.2). Licensee further acknowledges that its use of the Product Trademarks or POZEN Trademarks will not create in Licensee any
right, title or interest in such trademarks, except as a licensee, and that all use of such trademarks and the goodwill generated thereby will inure solely to the benefit of POZEN. 
  
 6.4 Establishment of Units and Minimum Royalties. Prior to the commercial launch of any Product other than the
Initial Product, the Parties will agree on the applicable definitions for a “Unit” of such Product and the “Per Unit Minimum” (as set forth in the table on Exhibit F) for such Product. 
  
 7. DILIGENCE 
  
 7.1 General Diligence Obligations. Licensee will use commercially
reasonable efforts to perform the activities set forth under each Marketing Plan. Licensee will promote, market, sell and distribute the Products in the Field in each country of the Territory continuously during the term of this Agreement by
applying efforts and resources as reasonably required to maximize sales of the Products throughout the Territory and at least equal to the efforts and resources normally used by Licensee for a product owned by it which has a similar market potential
and is at a similar stage in its product life cycle as the applicable Product. All efforts of Licensee’s Affiliates will be considered efforts of Licensee for the purpose of determining Licensee’s compliance with its obligations under this
Section 7.1. 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 15 

 7.2 Minimum Launch Diligence Obligations. Without limiting the diligence obligations of Section
7.1 above, Licensee will launch the commercial sale of each Product in each country in the Territory as soon as reasonably possible after receipt of Regulatory Approval for such Product in such country, but in no event later than [***] after such
receipt; provided, however, that such [***] period will be [***]. Notwithstanding the foregoing, if Licensee submits packaging artwork for the Initial Product pursuant to Section 4.3 of the Supply Agreement promptly after Regulatory Approval
for the Initial Product and commercial supply of the Initial Product is not available pursuant to the Supply Agreement due to the time required to incorporate such artwork into the manufacture of Initial Product, then such unavailability will not be
deemed to be “due to any act or omission by Licensee” for purposes of the foregoing sentence. 
  
 7.3 Minimum Commercialization Diligence Obligations. Without limiting the diligence obligations of Section 7.1 above, during the [***] of a Product
in a country in the Territory, Licensee will: (a) subject to pre-booked meetings in which Licensee has arranged to promote other products, promote such Product in the first detailing position with a full sales force in such country, covering both
primary care physicians and relevant specialists, (b) allocate to the promotion of such Product sales efforts greater than or equal to the sales efforts allocated by Licensee to any other prescription product of comparable market potential and stage
of product life cycle promoted by Licensee in the Territory during such period, and (c) use best efforts to pre-book meetings with physicians in such country for the promotion of such Product. 
  
 7.4 Diligence Limitations. 
  
 7.4.1 If Licensee determines that launching the Initial Product in a
country of the Territory would [***] or [***], then Licensee will provide POZEN with written notice of such determination and with copies of or access to all evidence considered by Licensee in making such determination. If Licensee determines that
it does not wish to launch a Product (other than the Initial Product) developed by POZEN and covered by the rights and licenses granted to Licensee under this Agreement, then Licensee will provide POZEN with written notice of such determination. If
Licensee determines at any time that the manufacture, use or sale of a Product in a country in the Territory would infringe the intellectual property rights of any Third Party, then Licensee will provide POZEN with written notice of such
determination. 
  
 7.4.2 In each event described in
subsection 7.4.1, the Parties will discuss whether Licensee should launch or sell the applicable Product in the applicable country. If the Parties agree that Licensee should not launch or sell such Product in such country, then Licensee will be
under no obligation under this Agreement to launch or sell such Product in such country; provided, however, that Licensee provides POZEN with an annual update, in writing, on the reasons for delaying or foregoing the launch or sale of
such Product in such country and, in each case, POZEN agrees that such launch or sale should not be undertaken. 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 16 

 7.4.3 If (a) pursuant to subsection 7.4.2, the Parties have discussed whether Licensee should
launch or sell the applicable Product in the applicable country, (b) Licensee has determined that it should not launch or sell such Product in such country, (c) POZEN disagrees with such determination, and (d) such disagreement is not resolved on or
before the date 60 days after the initial discussion between the Parties pursuant to subsection 7.4.2, then this Agreement will terminate with respect to such Product in such country at the end of such 60-day period. In such case, all of
Licensee’s rights and obligations under this Agreement with respect to the commercialization of such Product in such country, including without limitation the rights and licenses granted by POZEN to Licensee under Section 8.1 of this Agreement
with respect to such Product in such country, will terminate immediately. Any such termination will have no effect on Licensee’s rights and obligations under this Agreement to commercialize other Products in such country and to commercialize
such Product in other countries of the Territory. 
  
 7.5 Lack
of Diligence. To the extent POZEN or any supplier of the Product appointed by POZEN fulfills its Product supply obligations hereunder and under any supply agreement entered into (or, in the case of a supplier appointed by Licensee, to the extent
Licensee has used commercially reasonable efforts to obtain Product from such supplier and is in compliance with its obligations under its supply agreement with such supplier), and subject to Section 18.9 and any other event outside Licensee’s
reasonable control, any failure by Licensee to fulfill a diligence obligation set forth in Sections 7.2 and 7.3(a) of this Agreement will be deemed a material breach of this Agreement. Licensee’s fulfillment of the diligence obligations set
forth in Sections 7.2 and 7.3 of this Agreement will be taken into account when determining whether Licensee has fulfilled its obligations set forth in Section 7.1 of this Agreement, but will not be considered conclusive proof that such obligations
have also been fulfilled. 
  
 7.6 [***]. In the event
Licensee receives notice from a Third Party alleging that the manufacture, use or sale of the Product in the Territory infringes such Third Party’s intellectual property rights, Licensee shall provide POZEN with prompt written notice thereof
and the Parties shall consult with each other in good faith regarding such allegation. Licensee shall consider POZEN’s suggestions and comments regarding such alleged infringement [***] set out in this Agreement, and shall, [***] set out in
this Agreement. 
  
 8. LICENSES AND OTHER
RIGHTS 
  
 8.1 License Grants to Licensee. 
  
 8.1.1 Subject to the terms and conditions set forth in this Agreement,
POZEN hereby grants to Licensee an exclusive, royalty-bearing license under the Licensed Technology to market, sell, offer to sell and distribute for sale Products in the Field within the Territory. 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 17 

 8.1.2 Subject to the terms and conditions set forth in this Agreement and upon termination of the
Supply Agreement executed between the Parties, POZEN will grant to Licensee solely for Licensee’s exclusive sale and distribution for sale within the Field within the Territory a non-exclusive, royalty-free license under the Licensed Technology
to use, make, have made, import and export Products in the Field within the Territory. 
  
 8.1.3 Subject to the terms and conditions set forth in this Agreement (including subsection 6.3.2 above), POZEN hereby grants to Licensee an exclusive, royalty-free license to use the Product Trademarks and
POZEN Trademarks in connection with the sale and distribution of Products in the Field within the Territory. 
  
 8.1.4 Licensee has the right to grant sublicenses under the licenses granted in this Section 8.1 only to Affiliates; provided,
however, that each such sublicense grant is subject to the terms of this Agreement. Any act or omission by a sublicensee of Licensee that would, if committed by Licensee, constitute a breach of this Agreement by Licensee, will be deemed a
breach of this Agreement by Licensee. 
  
 8.2 Negative
Covenants. 
  
 8.2.1 Licensee hereby covenants and
agrees that it shall not undertake, nor authorize any Affiliate of Licensee to undertake, any of the following activities: (a) conducting clinical trials or other development of a Product outside the Field or the Territory; (b) filing for Marketing
Approval of any Product outside the Field or the Territory; (c) using or practicing any Licensed Technology or Product Trademarks outside the Territory; (d) granting a sublicense to any Third Party of any rights or licenses granted to Licensee under
this Agreement; (e) developing, distributing or commercializing any Product for non-prescription sale with or without use or practice of the Licensed Technology or Product Trademarks; (f) applying for any Regulatory Approval that would allow the
over-the-counter sale of any Product in the Territory; (g) directly or indirectly marketing and selling any Product to patients without a prescription for the Product; (h) [***]; or (i) [***]. For purposes of clarification, the [***] shall not be
construed to limit Nycomed’s non-use and non-disclosure obligations with respect to POZEN’s Confidential Information under Section 14 throughout the world. This negative covenant is subject to any rights that may have been granted to
Licensee, or that Licensee may otherwise have [***]. POZEN hereby exclusively reserves all rights with respect to the Product outside the Territory. 
  
 8.2.2 POZEN will not, during the Term, grant any right to any Third Party relating to the Licensed Technology in the Field in the Territory which
would conflict with the rights granted to Nycomed hereunder. 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 18 

 8.2.3 POZEN shall not, during the Term, on its own part or through its Affiliates or Third Parties
market, distribute or sell any Competing Product in the Territory. 
  
 8.3 License Grants to POZEN. Licensee hereby grants to POZEN a fully paid, exclusive right and license, with the right to grant sublicenses, under any Patents or Know-How Controlled by Licensee or any of its Affiliates, (a) to use
outside the Territory any clinical and non-clinical data generated by or on behalf of Licensee in the course of developing Products, (b) to reference any Marketing Approvals obtained for Products in the Territory, for the purpose of developing and
pursuing Marketing Approvals for Products outside the Territory, and (c) to use and reference any clinical and non-clinical data and Marketing Approvals obtained for Products in the Territory, for the purpose of developing and pursuing Marketing
Approvals for other products or for Products outside the Territory. 
  
 9. COMPENSATION 
  
 9.1
License Fees. As partial consideration for the rights and licenses granted under this Agreement with respect to the Products, Licensee will pay to POZEN a non-refundable, non-creditable license fee (the “Initial License Fee”) of
US$500,000 within 5 days after the Effective Date. 
  
 9.2
Milestones. 
  
 9.2.1 If the POZEN MAA receives
approval in the United Kingdom [***], then Licensee will make the non-refundable, non-creditable milestone payments set forth in Exhibit B to this Agreement. 
  

9.2.2 If the POZEN MAA receives approval in the United Kingdom [***], then Licensee will make the non-refundable, non-creditable milestone
payments set forth in Exhibit C to this Agreement. 
  
 9.2.3
If the POZEN MAA receives approval in the United Kingdom [***], then Licensee will make the non-refundable, non-creditable milestone payments set forth in Exhibit D to this Agreement. 
  
 9.2.4 In any event, Licensee will pay to POZEN a non-refundable,
non-creditable milestone payment in the amount of [***]$[***] for which a Product receives Marketing Approval anywhere in the Territory, within 15 days from receipt by Licensee of evidence of the receipt of such Marketing Approval. 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 19 

 9.3 Royalties. 
  
 9.3.1 Royalty Amount. Subject to the adjustments provided for in this Section 9.3, Licensee will pay to POZEN a
royalty equal to the greater of: (a) [***]% of Net Sales of any Product by Licensee or its Affiliates in any country in the Territory, and (b) the Minimum Royalty Amount for such Product in such country. [***]. 
  
 9.3.2 Royalty Term. Royalties due under the preceding subsection 9.3.1
will be payable on a country-by-country and Product-by-Product basis until the later of: (i) the expiration of the last-to-expire issued Patent within the Licensed Technology containing a Valid Claim covering such Product in such country, or (ii) 15
years from the first commercial sale of such Product in such country (the “Royalty Term”). 
  
 9.3.3 [***] 
  
 (a) Notwithstanding the provisions of subsection 9.3.1, if a Product is [***] in a particular country in the Territory [***], then the royalty
amounts described in subsection 9.3.1 of this Agreement [***] with respect to such Product in such country, [***] in such country, and: 
  
 (i) such [***], in the [***]%[***]%, of the total unit sales of wholesalers to pharmacies of [***] (as evidenced by a report from a data source
accepted in the pharmaceutical industry, [***]), in which case the royalty payable pursuant to subsection 9.3.1 on such Product in such country [***]%; or 
  
 (ii) such [***] % [***] of the total unit sales of wholesalers to pharmacies of [***] (as evidenced by a report from a data source accepted in the
pharmaceutical industry, [***]), in which case the royalty payable pursuant to subsection 9.3.1 on such Product in such country [***]%. 
  
 (b) Notwithstanding the provisions of subsection 9.3.1, during such time as POZEN is providing Nycomed under the Supply Agreement with Initial
Product [***], the royalty payable pursuant to subsection 9.3.1 on sales of Initial Product [***]%. The royalty [***] set forth in this subsection 9.3.3(b) will automatically expire upon the later of: (i) [***], and (ii) the [***]. 
  
 9.4 Reports; Payment Method; Currency. Licensee will provide POZEN
within 25 days after the end of each calendar quarter with a report stating the Unit volume of Products sold or otherwise disposed of in each country of the Territory and providing the calculations for the Net Sales, Minimum Royalty Amount, and
royalties due. Within 30 days after the end of each calendar quarter, Licensee will transfer, by wire, the amount of 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 20 

 royalties due to such bank account as POZEN may indicate from time to time. Payment of all royalties due hereunder will
be made in the currency in which Net Sales accrued. Any payments or portions thereof due hereunder that are not paid on the date such payments are due under this Agreement will bear interest at a per annum rate equal to the lesser of (a) the prime
rate as published in The Wall Street Journal, Eastern Edition, on the first day of each calendar quarter in which such payments are overdue, plus 2 percentage points, and (b) the maximum rate permitted by law, calculated on the number of days
such payment is delinquent, compounded monthly. 
  
 9.5 Blocked
Currency. In each country where the local currency is blocked and cannot be removed from the country, royalties accrued in that country will be paid by Licensee in the country in local currency by deposit in a local bank designated by POZEN,
unless the Parties otherwise agree in writing. 
  
 9.6
Taxes. Licensee will have the right to withhold taxes in the event that authorities in any country require the withholding of taxes on amounts paid hereunder to POZEN. Such taxes will be deducted by Licensee from such payment and will be paid by
Licensee to the proper taxing authority on behalf of POZEN. Licensee will promptly secure and send to POZEN proof evidencing payment of such taxes withheld and paid by Licensee for the benefit of POZEN. Licensee will assist POZEN in claiming
exemption from such deductions or withholdings under any applicable income tax treaty by providing such documentation as may be reasonably required by POZEN to claim such exemption. 
  
 9.7 Audit Rights; Adjustments. 
  
 9.7.1 Licensee will permit an independent certified public accountant designated by POZEN and reasonably acceptable
to Licensee (the “Auditor”), to have access to Licensee’s records and books during regular business hours for the sole purpose of determining the accuracy of the amounts reported and actually paid or otherwise payable to POZEN
under the terms of this Agreement (the “Audit”). Any Audit will cover a period not to exceed 3 years immediately preceding such audit. POZEN will bear all costs and expenses in connection with the Audit; provided,
however, that if any Audit reveals an understatement of Net Sales greater than 5% of the stated amount, then Licensee will bear all costs and expenses in connection with such Audit. Any such Audit will be performed upon at least 30 calendar
days’ prior written notice during regular business hours, and not more than once in each calendar year during the term of this Agreement and during each calendar year in the 3-year period following expiration or termination of this Agreement.

  
 9.7.2 The Auditor will execute a written
confidentiality agreement with Licensee and will disclose to POZEN only the amount and accuracy of payments reported and 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 21 

 actually paid or otherwise payable under this Agreement. The Auditor will send a copy of the report to Licensee at the
same time it is sent to POZEN. The report sent to Licensee will also include the methodology and calculations used to determine the results. 
  
 9.7.3 If the Audit results in a determination that Net Sales have been overstated, then POZEN will repay the amount of any resulting overpayment
within 30 days after receipt of the Auditor’s report with interest from the date originally due, calculated at a per annum rate equal to the prime rate as published in The Wall Street Journal, Eastern Edition, on the first day of each
calendar quarter in which such payments are overdue, plus 2 percentage points. 
  
 9.7.4 If the Audit results in a determination that Net Sales have been understated, then any resulting underpayment will be paid to POZEN within 30 days after receipt of the Auditor’s report with interest
from the date originally due, calculated at a per annum rate equal to the prime rate as published in The Wall Street Journal, Eastern Edition, on the first day of each calendar quarter in which such payments are overdue, plus 2 percentage
points. 
  
 10. INTELLECTUAL PROPERTY

  
 10.1 Licensee’s Obligation to Inform. Licensee
will promptly disclose to POZEN all Improvements made solely by Licensee, its Affiliates or their Third Party contractors, or jointly by Licensee, its Affiliates or their Third Party contractors. Information provided by Licensee to POZEN with
respect to such Improvements will be in reasonable detail but in no circumstance less than would be sufficient to permit an understanding of the nature of the Improvements by a practitioner reasonably skilled in the relevant technical or scientific
area. 
  
 10.2 POZEN’s Obligation to Inform. As of the
Effective Date, POZEN has disclosed to Nycomed the complete text of all pending patent applications included in the POZEN Patents as of the Effective Date, as well as copies of all correspondence concerning the prosecution thereof made or received
by or on behalf of POZEN to or from patent offices and any information or correspondence received by or on behalf of POZEN from patent offices concerning the institution of any interference, opposition, re-examination, reissue, revocation,
nullification or any official proceeding involving any POZEN Patents, in each case to the extent in existence as of the Effective Date. In addition, during the Term, POZEN will disclose to Nycomed the complete text of all patent applications
included in the POZEN Patents that are filed after the Effective Date, as well as copies of all correspondence concerning the prosecution thereof made or received by or on behalf of POZEN to or from patent offices and any information or
correspondence received by or on behalf of POZEN from patent offices concerning the institution of any interference, opposition, re-examination, reissue, revocation, nullification or any official proceeding 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 22 

 involving any POZEN Patents after the Effective Date, and if possible transmit such information electronically to Nycomed
or ship such materials DDU (ICC INCOTERMS 2000) to a place of destination to be named by Nycomed within 10 days after the Effective Date. POZEN shall promptly inform Nycomed of the issuance of any POZEN Patents. 
  
 10.3 Ownership. 
  
 10.3.1 Licensed Technology. All right, title and interest in and to
the Licensed Technology will remain exclusively with POZEN, subject only to the licenses granted to Licensee under this Agreement. 
  
 10.3.2 Improvements. POZEN will own all right, title and interest in and to the Improvements, including any intellectual property rights
appurtenant thereto, subject only to the licenses granted to Licensee under this Agreement. Licensee agrees to assign and hereby assigns to POZEN all of its rights, title and interest in Improvements, and will ensure that any agreements with
Affiliates and/or Third Party contractors include the assignment of such Improvements to Licensee or directly to POZEN. Licensee will cooperate with POZEN with respect to patent filing, prosecution and enforcement of such Improvements, and POZEN
will reimburse Licensee for any internal costs (at then-standard FTE rates) and for out-of-pocket expenses incurred by Nycomed in connection with such cooperation (such costs to be agreed upon in writing by the Parties prior to initiation of any
such support). For the avoidance of doubt, any such Improvement assigned to POZEN is part of the Licensed Technology licensed to Licensee pursuant to this Agreement, and no royalties in addition to those set forth in Section 9.3 of this Agreement
will be due in connection with the licenses granted to Licensee to such Improvements under this Agreement. 
  
 10.4 Patent Filing, Prosecution and Maintenance. Subject to the terms and conditions set forth in this Section 10.4, POZEN has the exclusive right
to file, prosecute and maintain all POZEN Patents or Patents claiming or covering Improvements. Subject to the terms and conditions set forth in this Section 10.4, POZEN will use commercially reasonable efforts to obtain and maintain during the Term
POZEN Patents and any Patents claiming or covering Improvements; provided, however, that POZEN will not be required to undertake or defend any legal action or challenge to such Patents. 
  
 10.4.1 With respect to POZEN Patents as of the Effective Date, POZEN
will have the obligation to prosecute and, for issued Patents, maintain such Patents during the Term. 
  
 10.4.2 POZEN shall consent to and execute the necessary documents in order to have Licensee registered as licensee of the Products with the local
patent and trademark departments in the Territory. 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 23 

 10.4.3 POZEN will apply for patent protection in all countries of the Territory for any
Improvement that in POZEN’s reasonable opinion is patentable. If POZEN elects not to file a patent application claiming or covering an Improvement in a particular country, then POZEN will give prompt written notice to Licensee of such decision,
but in any event within 30 days before the time limit, if any, set forth in the appropriate laws and regulations for the filing of such application. In such case, Licensee may elect at its sole discretion to undertake the preparation, filing,
prosecution or maintenance of a patent application claiming or covering such Improvement in such country at its sole expense. Notwithstanding anything in this Agreement, Licensee will own any such patent application and patents issuing therefrom and
will be solely responsible for all associated costs,. POZEN will execute such documents and perform such acts as may be reasonably necessary for Licensee to commence such prosecution. 
  
 10.4.4 Licensee hereby covenants and agrees not to enforce against POZEN, its Affiliates or licensees of Product any
Patent Controlled by Licensee that claims or covers one or more Improvements obtained under this Section 10.4. 
  
 10.5 Enforcement Rights. 
  
 10.5.1 Notification of Infringement. If either Party learns of any misappropriation of any proprietary Product information such as trade secrets,
copyrights or Licensee Trademarks, POZEN Trademarks or Product Trademarks (the “Product Rights”) or any infringement or threatened infringement by a Third Party of the Licensed Technology or any Patent covering an Improvement, in
each case, in the Field and in the Territory, such Party will promptly notify the other Party and will provide such other Party with all available evidence of such misappropriation or infringement. 
  
 10.5.2 Enforcement of Patents and Product Rights in the Territory.

  
 (a) Licensee will have the first right, but not the
obligation, to institute, prosecute and control any action or proceeding with respect to infringement in the Field and in the Territory of the Licensed Technology or any Patent covering an Improvement, or any misappropriation of Product Rights in
the Field and in the Territory, by counsel of its own choice, and will consult with POZEN on any actions that Licensee proposes to take in such action or proceeding. The costs of such defense will be equally shared between the parties in accordance
with subsection 10.5.4. Notwithstanding subsection 10.5.4, POZEN will have the right, at its own expense, to be represented in any such action by counsel of its own choice; provided, however, that this shall not relieve POZEN from its obligation to
share the costs incurred by the common legal counsel. 
  
 (b)
If Licensee fails to bring an action or proceeding or otherwise take appropriate action in Licensee’s discretion to abate such infringement or misappropriation in the 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 24 

 Field and in the Territory within a period of 90 days of written notice by POZEN to Licensee requesting such action,
POZEN will have the right, but not the obligation, to bring and control, by counsel of its own choice, any such infringement or misappropriation action or proceeding. Licensee will cooperate with POZEN in any such action or proceeding brought by
POZEN against a Third Party, and will have the right to consult with POZEN and to participate in and be represented by independent counsel in such litigation at its own expense. 
  
 (c) If a Party brings any action or proceeding under this subsection 10.5.2, the other Party agrees, at the request
of the first Party, to be joined as a party plaintiff if necessary to prosecute the action or proceeding and to give the first Party reasonable assistance and authority to file and prosecute the suit, including without limitation providing
commercial, clinical or manufacturing data available to the Parties, executing necessary documents, and providing expert support. 
  
 10.5.3 Settlement with a Third Party. The Party that controls the prosecution of a given action under this Section 10.5 will also have the right to
control settlement of such action; provided, however, that no settlement will be entered into which would limit the scope or enforceability of any POZEN Patents or a Patent covering Improvements without the written consent of POZEN,
such consent not to be unreasonably withheld. 
  
 10.5.4
Enforcement Costs and Awards. Any costs incurred in connection with an action or proceeding brought by a Party pursuant to subsection 10.5.2 of this Agreement will be shared equally between the Parties. Any damage award resulting from any such
action, after reimbursement of each Party’s expenses, will be deemed Net Sales of Licensee in the applicable country or countries, and will be subject to the royalties set forth in Section 9.3 of this Agreement. If a Party does not want to bear
an equal share of the costs of such an action, such Party may opt out of such costs by providing the other Party with adequate notice, which shall be given before the initiation of the trial, of its intention not to participate in the costs of the
enforcement action. In such event, the Party opting out of the enforcement costs will continue to cooperate with the enforcing Party at the enforcing Party’s expense, and the enforcing Party will retain the full amount of any damage awards
resulting from such enforcement action. 
  
 10.5.5 Decision Not
to Pursue. POZEN will have the right to prevent Licensee from undertaking an enforcement action under subsection 10.5.2 of this Agreement for strategic reasons (including, without limitation, protection in other jurisdictions of Patents in the
Licensed Technology); provided, however, that if a Third Party is commercializing a Competing Product that infringes a Patent in the Licensed Technology in a country in the Territory, the royalty reduction mechanism set forth in
subsection 9.3.3(a) of this Agreement will apply with respect to any Product in such country with which such Third Party’s product is a Competing Product. 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 25 

 10.6 Defense and Settlement of Third Party Claims. 
  
 10.6.1 Defense. If a Third Party asserts that a patent, trade secret,
or other intangible right owned or exclusively licensed by it is infringed or misappropriated by the manufacture, use, sale, or offer for sale of a Product in the Field in the Territory, the Parties will establish a plan for a common defense and
Licensee will manage such common defense plan, subject to subsection 10.6.2 below. The costs of any such defense to such action incurred by one or both of the Parties pursuant to such plan (including the costs of any judgment, award, decree or
settlement) will be shared equally between the parties. 
  
 10.6.2 Settlement with a Third Party. Either Party will also have the right to control settlement of a claim described in subsection 10.6.1 above; provided, however, that no settlement will be entered into without the
written consent of the other Party. If there is no agreement between the Parties as to any proposed settlement, then the dispute will be decided pursuant to Section 17 of this Agreement. 
  
 10.7 Indemnification. Indemnification of any loss resulting from the infringement of any third party rights by the
use or practice of the Licensed Technology or the commercialization of any Product will be governed exclusively by Section 12 of this Agreement. 
  
 11. REPRESENTATIONS AND WARRANTIES 
  
 11.1 Mutual Representations and Warranties. Each of the Parties hereby represents and warrants to the other Party that: 
  
 11.1.1 such Party is a corporation duly organized, validly existing
and in good standing under the laws of the state in which it is incorporated; 
  
 11.1.2 this Agreement is a legal and valid obligation binding upon such Party and enforceable against such Party in accordance with its terms; 
  
 11.1.3 the execution, delivery and performance of this Agreement by such Party does not conflict with any agreement,
instrument or understanding, oral or written, to which it is a Party or by which it is bound; 
  
 11.1.4 to the best of such Party’s knowledge, the execution, delivery and performance of this Agreement by such Party does not violate any law or regulation of any court, governmental body or
administrative or other agency having jurisdiction over such Party; 
  
 11.1.5 such Party has the full power and authority to enter into this Agreement and to carry out the obligations contemplated hereby; 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 26 

 11.1.6 such Party has not, and during the Term will not, grant any right to any Third Party
relating to its respective Patents and Know-How which would conflict with the rights granted to the other Party hereunder; 
  
 11.1.7 to the best of such Party’s knowledge, neither it, nor any of its employees, officers, subcontractors or consultants who will perform
any Development Program (i) has been debarred or convicted of a crime for which an entity or person could be debarred under 21 U.S.C. Section 335a, or (ii) is under indictment for a crime for which a person or entity could be debarred under 21
U.S.C. Section 335a; and 
  
 11.1.8 such Party has taken
all necessary corporate action on its part to authorize the execution and delivery of this Agreement. 
  
 11.2 POZEN Representations and Warranties. POZEN hereby represents and warrants to Licensee that: 
  
 11.2.1 to the best of POZEN’s knowledge as of the Effective
Date, there is no Third Party infringing any of the Patents included in the Licensed Technology or misappropriating or using any of the Know-How included in the Licensed Technology contrary to the rights granted to Licensee pursuant to this
Agreement; 
  
 11.2.2 POZEN has obtained the assignment of
all interests and all rights of any and all Third Parties (including, but not limited to employees) with respect to the POZEN Patents; 
  
 11.2.3 as of the Effective Date, POZEN has not been served with any interference action or litigation in the Territory with respect to the Licensed
Technology, and POZEN has not received any written communication which expressly threatens interference actions or other litigation before any patent and trademark office, court, or any other governmental entity in the Territory in regard to any
such Patents or Product Trademarks, or claiming misappropriation in the Territory of any Licensed Know-How; 
  
 11.2.4 as of the Effective Date, POZEN has obtained an opinion from legal counsel with respect to POZEN’s freedom to operate under any Patents
included in the Licensed Technology; and 
  
 11.2.5 to the
best of POZEN’s knowledge as of the Effective Date, [***] in the preceding clause, the use of the Licensed Technology on the terms set out in this Agreement does not infringe the intellectual property rights of any Third Party within the
Territory or constitute a misappropriation of the trade secrets or other intellectual property rights of any Third Party within the Territory. 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 27 

 11.2.6 POZEN has provided Licensee’s internal patent counsel, during a due diligence meeting
conducted on the 4th to the 5th of November, 2002, with access to complete copies of the most current versions of all pending patent applications included in the POZEN Patents and all correspondence between POZEN and any patent office with respect
to the pending patent applications included in the POZEN Patents as of the Effective Date, and such copies accurately reflect the scope of such patent applications as of the Effective Date. 
  
 11.3 Limitation of Warranty. EXCEPT AS EXPRESSLY STATED IN THIS
AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY, AND EACH PARTY EXPRESSLY DISCLAIMS ALL IMPLIED WARRANTIES, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT, WITH RESPECT TO ANY MATERIALS,
INFORMATION, SERVICES, OR LICENSES PROVIDED TO THE OTHER PARTY PURSUANT TO THIS AGREEMENT. 
  
 11.4 Performance by Affiliates. The Parties recognize that each Party may perform some or all of its obligations under this Agreement through Affiliates; provided, however, that each Party will
remain responsible for the performance by its Affiliates and will cause its Affiliates to comply with the provisions of this Agreement in connection with such performance and any act or omission committed by an Affiliate shall be deemed to have been
conducted by the Party itself. Each Party hereby expressly waives any requirement that the other Party exhaust any right, power or remedy, or proceeds against an Affiliate, for any obligation or performance hereunder prior to proceeding directly
against such Party. 
  
 12.
INDEMNIFICATION 
  
 12.1 Indemnification by Licensee.
Licensee will indemnify, defend and hold POZEN and its directors, officers, employees, agents and Affiliates harmless from and against any liabilities, damages, costs or expenses, including reasonable attorneys’ fees (collectively,
“Losses”), which arise out of, relate to or result from: (a) the breach by Licensee of any of its representations, warranties or obligations contained within this Agreement; or (b) any claim, lawsuit or other action by a Third Party
arising from or relating to the development, manufacture, use, sale, offer to sell, sale and importation by Licensee, its Affiliates or subcontractors of Products in the Field in the Territory. Notwithstanding the foregoing, Licensee will not
indemnify POZEN for any Losses to the extent that Licensee is entitled to seek indemnification from POZEN for such Losses under Section 12.2 of this Agreement. 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 28 

 12.2 Indemnification by POZEN. POZEN will indemnify, defend and hold Licensee and its directors,
officers, employees, agents and Affiliates harmless from and against any Losses which arise from any claim, lawsuit or other action to the extent such Losses arise out of, relate to or result from: (a) the breach by POZEN of any of its
representations, warranties or obligations contained within this Agreement; or (b) any claim, lawsuit or other action by a Third Party arising from or relating to the development, transportation or manufacture by POZEN of Products in the Field in
the Territory. Notwithstanding the foregoing, POZEN will not indemnify Licensee for any Losses to the extent that POZEN is entitled to seek indemnification from Licensee for such Losses under Section 12.1 of this Agreement. 
  
 12.3 Indemnification Procedures. A Party which intends to claim
indemnification under Section 12.1 or 12.2 of this Agreement (the “Indemnitee”) will promptly notify the other Party (the “Indemnitor”) in writing of any claim, lawsuit or other action in respect of which the Indemnitee or
any of its directors, officers, employees, and Affiliates intend to claim such indemnification within a reasonable period of time after the assertion of such claim; provided, however, that the failure to provide written notice of such
claim within a reasonable period of time will not relieve the Indemnitor of any of its obligations hereunder, except to the extent that the Indemnitor is prejudiced by such failure to provide prompt notice. The Indemnitor will have the right to
assume the complete control of the defense, compromise or settlement of any such claim without the prior written consent of such Indemnitee, which such consent will not be unreasonably withheld; provided, however, that Indemnitee will have
the right to withhold such consent in its sole discretion if such defense, compromise or settlement includes any admission of wrongdoing on the part of an Indemnitee, or limits the scope of any claims in or enforceability of any Patents owned by or
licensed to the Indemnitee). The Indemnitor may at its own expense, employ legal counsel to defend the claim at issue. At any time after Indemnitor has assumed defense of a claim, the Indemnitor may exercise, on behalf of the Indemnitee, any rights
which may mitigate the extent or amount of such claim; provided, however, the Indemnitee: (a) may, in its sole discretion and at its own expense, employ legal counsel to represent it (in addition to the legal counsel employed by the
Indemnitor) in any such matter, and in such event legal counsel selected by the Indemnitee will be required to confer and cooperate with such counsel of the Indemnitor in such defense, compromise or settlement for the purpose of informing and
sharing information with the Indemnitor; (b) will, at its own expense, make available to Indemnitor those employees, officers and directors or Indemnitee whose assistance, testimony or presence is necessary, useful or appropriate to assist the
Indemnitor in evaluating and in defending any such claim; provided, however, that any such access will be conducted in such a manner as not to interfere unreasonably with the operations of the businesses of Indemnitee; and (c) will
otherwise fully cooperate with the Indemnitor and its legal counsel in the investigation and defense of such claim. The rights and remedies provided pursuant to this Section 12 are the sole and exclusive remedies of the Parties hereto with respect
to Losses. 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 29 

 12.4 Insurance. Each Party will maintain commercially reasonable insurance coverage commensurate
with its obligations under this Agreement. Such commercially reasonable insurance coverage will include [***] $ [***]. 
  
 13. LIMITATION OF LIABILITY 
  
 IN NO EVENT WILL EITHER PARTY BE LIABLE TO THE OTHER PARTY FOR INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING, BUT NOT LIMITED TO, ANY
CLAIM FOR DAMAGES BASED UPON LOST PROFITS, BUT EXCLUDING ANY CLAIMS BASED UPON THE OBLIGATIONS SET FORTH IN SECTIONS 12 AND 14 OF THIS AGREEMENT. 
  
 14. CONFIDENTIALITY, PUBLICATIONS, PUBLICITY 
  
 14.1 Confidential Information. Any information or materials communicated by one Party to the other Party pursuant to
this Agreement or the Confidential Disclosure Agreement between the Parties dated [***] will be deemed “Confidential Information” of the disclosing Party if marked “confidential” or with a similar legend, or if disclosed orally
or visually, if identified as being confidential at the time of such oral or visual disclosure, and thereafter reduced to writing, marked “confidential” or with a similar legend, and sent to the other Party within 30 days of such oral or
visual disclosure, or which information or materials would, due to the nature thereof or the circumstances surrounding disclosure, appear to a reasonable person to be confidential or proprietary. Notwithstanding the preceding sentence,
“Confidential Information” will not be deemed to include information that the receiving Party can demonstrate, by competent written proof: 
  
 14.1.1 At the time of disclosure is published or is publicly known or otherwise in the public domain, other than through any act or omission by the
receiving Party; 
  
 14.1.2 Was already known to the
receiving Party, other than under an obligation of confidentiality or non-use, prior to the time of disclosure; 
  
 14.1.3 Is disclosed to the receiving Party in good faith, without an obligation of confidentiality, by a Third Party not under any obligation of
confidence with respect to such information; or 
  
 14.1.4
Is independently developed by the receiving Party without use of or reference to the disclosing Party’s Confidential Information. 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 30 

 14.2 Treatment of Confidential Information. The Parties agree that during the term of this
Agreement and for 7 years after its expiration or termination for any reason whatsoever, a Party receiving Confidential Information of the other Party will: (a) treat any such Confidential Information disclosed to it by the other Party as strictly
confidential; (b) except as necessary in the performance of this Agreement, not disclose such Confidential Information to Third Parties without the prior written consent of the other Party, other than to its Affiliates, Sublicensees, collaborators
or any consultants, provided that such disclosure be under confidentiality agreements with provisions comparable to those contained in this Agreement; (c) not use such Confidential Information for purposes other than those authorized expressly
herein; and (d) use reasonable efforts to prevent inadvertent disclosure of such Confidential Information. 
  
 14.3 Access. Access to Confidential Information will be limited to those employees or consultants of the Party receiving such information or of
such Party’s Affiliates who reasonably require such information in order to carry out activities authorized pursuant to this Agreement. Such employees or consultants will be advised of the confidential nature of the Confidential Information and
the related confidentiality undertaking. 
  
 14.4 Permitted
Disclosures. Notwithstanding any other provision in this Agreement, a receiving Party may disclose Confidential Information of the disclosing Party to the extent such disclosure is required by law or court order, provided that the receiving
Party gives the disclosing Party prompt written notice of the requirement to disclose and reasonably cooperates with the disclosing Party to seek a protective order or other restrictions on the disclosure of such Confidential Information of the
disclosing Party. Any such required disclosure will be limited only to that Confidential Information that is required to be disclosed and such disclosed Confidential Information will remain Confidential Information hereunder despite the required
disclosure. 
  
 14.5 Return of Confidential Information.
Upon termination or expiration of this Agreement, each Party hereto and its Affiliates will return all Confidential Information of the other Party in their possession to the other Party; provided, however, that each Party may retain: (a) a single
archival copy of the Confidential Information of the other Party solely for the purpose of determining the extent of disclosure of Confidential Information hereunder and assuring compliance with the surviving provisions of this Agreement; (b) any
portion of the Confidential Information of the other Party which is contained in laboratory notebooks; and (c) any portion of the Confidential Information of the other Party which a Party is required by mandatory applicable law to retain.

  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 31 

 14.6 Confidentiality of the Agreement Terms. Neither Party will disclose the terms of this
Agreement to any Third Party without the prior written consent of the other Party; provided, however, that either Party may disclose the terms of this Agreement to actual or prospective investors and corporate partners (including
Sublicensees), to a Party’s accountants, attorneys and other professional advisors, and as required by applicable laws and regulations of the U.S. Securities and Exchange Commission and any stock exchange on which a Party’s stock is
traded. 
  
 14.7 Publications. Neither Party may present or
publish research results arising from this Agreement, including, without limitation, research results which relate to the use of the Licensed Technology in the Field, in a thesis, scientific publication, or conference, without the prior written
consent of the other Party. The presentations or publications will be presented in writing in the English language, will be presented to the other Party for review and comment at least 30 days prior to the time which the presentation or publication
is proposed for submission to any Third Party. Within 30 days after its receipt of such presentation or publication and at least 5 business days prior to the time which the presentation or publication is proposed for submission to any Third Party,
the other Party will provide notice whether it has any comments or objection to the proposed presentation or publication. The submitting Party will consider in good faith all comments by the reviewing Party. If a reasonable objection is raised,
including for example because the contents of the presentation or publication contain patentable subject matter for which patent protection should be sought, or because the presentation or publication discloses Confidential Information of the other
Party which constitutes proprietary trade secrets or Know-How, then submission of the presentation or publication will be delayed, unless and until such time as consent to submission of the presentation or publication is given, such consent not to
be unreasonably withheld. Each Party may be acknowledged on any publication or presentation by the other Party in accordance with generally accepted rules of authorship. 
  
 14.8 Publicity. Neither Party will make any public announcement concerning the existence of or the terms of this
Agreement, without the prior written approval of the other Party with regard to the form, content and precise timing of such announcement, except such as may be required to be made by either Party in order to comply with applicable law, regulations,
court order, or tax or securities filings. Such consent will not be unreasonably withheld or delayed by such other Party. Prior to any such public announcement, the Party wishing to make the announcement will submit a draft of the proposed
announcement to the other Party not less than 72 hours in advance to enable the other Party to consider and comment thereon. Notwithstanding anything to the contrary in this Agreement, nothing in this Section 14.8 is intended to prohibit either
Party from republishing or restating information relating to this Agreement that has already been approved by the other Party for use in a prior press release or public announcement. 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 32 

 15. TERM AND TERMINATION 
  
 15.1 Term of the Agreement. The term of this Agreement (the
“Term”) will commence on the Effective Date and, unless terminated earlier pursuant to this Section 15, will expire on a country-by-country basis upon the later of (a) the date of expiration of all royalty obligations in a given country in
the Territory pursuant to subsection 9.3.2 of this Agreement, and (b) the date 15 years after the date of first commercial sale of a Product in such country under this Agreement. 
  
 15.2 Termination for Material Breach. In the event of a material breach of this Agreement by either Party, which is
not cured within 60 days following receipt of written notice of the such breach from the non-breaching Party, the non-breaching Party will have the right to terminate this Agreement by written notification to the other Party, effective immediately
upon receipt. 
  
 15.3 Termination for MAA Failure. If the
POZEN MAA is not approved by [***], then Licensee may in its sole discretion terminate this Agreement upon written notice to POZEN. 
  
 15.4 Termination for MAA Withdrawal. 
  
 15.4.1 If, pursuant to subsection 4.2.2 of this Agreement, POZEN elects to Withdraw the POZEN MAA, then this Agreement will terminate 30 days after
the effective date of such Withdrawal. 
  
 15.4.2 If,
pursuant to subsection 4.2.2 of this Agreement, POZEN elects to Withdraw any MAA filed in any country of the Territory, then this Agreement will terminate with respect to such country 30 days after the effective date of such Withdrawal. In such
case, the definition of “Territory” set forth in Section 1 of this Agreement will be deemed amended to exclude such country, and this Agreement, including all the rights and licenses granted by POZEN to Licensee under Section 8.1 of this
Agreement will terminate immediately with respect to such country. 
  
 15.4.3 If, pursuant to subsection 4.2.2 of this Agreement, POZEN elects to Withdraw the POZEN MAA or any MAA filed in any country of the Territory, then POZEN will pay Licensee a withdrawal fee in the amount set forth in Exhibit E to
this Agreement within [***] of the effective date of such Withdrawal. 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 33 

 15.4.4 If, pursuant to Section 4.2 of the Supply Agreement, Nycomed terminates this Agreement
prior to approval of the POZEN MAA, then POZEN will pay Licensee a withdrawal fee in the amount set forth in Exhibit E to this Agreement within [***] of the effective date of such termination. 
  
 15.5 Termination for Bankruptcy. Either Party may immediately
terminate this Agreement upon the occurrence of either of the following: (a) the entry of a decree or order for relief by a court having jurisdiction in the premises in respect of the other Party in an involuntary case under any applicable national,
federal, or state insolvency or other similar law, and the continuance of any such decree or order unstayed and in effect for a period of sixty (60) consecutive days; or (b) the filing by the other Party of a petition for relief under any applicable
national, federal, or state insolvency or other similar law. All rights and licenses granted under or pursuant to this Agreement, including amendments hereto, by each Party to the other Party are, for all purposes of 11 U.S.C. Section 365(n),
licenses of rights to intellectual property as defined in Title 11. 
  
 15.6 Termination of Supply Agreement. If the Supply Agreement is terminated by POZEN for a breach of such agreement by Licensee, under the terms and conditions set forth therein, then POZEN will have the right to terminate this
Agreement by written notification to Licensee, effective immediately upon receipt. 
  

	16.	CONSEQUENCES OF TERMINATION 

  
 16.1 General. No termination of this Agreement will relieve any Party hereto from any liability which, at the time of such termination, has already
accrued to the other Party or which is attributable to a period prior to such termination, nor preclude either Party from pursuing any rights and remedies it may have under this Agreement or at law or in equity which accrued or are based upon any
event occurring prior to such termination. 
  
 16.2 Termination
Prior to Expiration by POZEN. If this Agreement is terminated pursuant to Sections 15.2, 15.3, 15.4.1, 15.5 or 15.6, then (i) the rights and licenses granted by POZEN to Licensee under Section 8.1 of this Agreement will terminate immediately;
(ii) all rights in the Products, trademarks, and Marketing Approvals as are necessary or useful to make, use, offer to sell, sell, or import a Product, will revert or be assigned to POZEN, and Licensee will promptly take all actions and execute such
documents as requested by POZEN to affect such transfer of Product rights to POZEN; (iii) Licensee will return all of POZEN’s Confidential Information within 60 days of such termination; (iv) Licensee will use reasonable efforts to transfer all
remaining Product to POZEN within 90 days of such termination and POZEN will pay to Licensee an amount equivalent to the Supply Price of such Product, provided such Product has at least 24 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 34 

 months of shelf life at the time of receipt by POZEN; (v) if Licensee has a source other than POZEN for commercial supply
of Product and POZEN does not have such a source, then subject to Licensee’s agreement with its manufacturer, Licensee will transfer or cause its manufacturer to transfer to POZEN or its designated manufacturer the complete manufacturing
process and associated documentation, including analytical methods, master batch records, and any Know-How pertaining to the manufacturing process; (vi) if Licensee manufactures its own commercial supply of Product and POZEN does not have an
independent source commercial supply of Product, then, in addition to the transfer of the manufacturing process described in the preceding clause (v), upon request of POZEN, Licensee will supply POZEN with POZEN’s requirements of Product at
[***] % [***] for a period of up to 3 years until POZEN, using commercially reasonable efforts, has established an independent source of commercial supply of Product; (vii) Licensee will hand over (implying no transfer of rights in any Licensee
Trademarks) and cause its Affiliates and agents to transfer to POZEN a full set of Product Promotional Materials; (viii) the rights granted by Licensee to POZEN under Section 8.3 of this Agreement will thereafter include all countries in the
Territory; and (ix) POZEN will have the exclusive right to develop, make, have made, use, offer to sell, sell, and import a Product in the Territory alone or with or through a Third Party. 
  
 16.3 Licenses Upon Expiration. Upon expiration of this Agreement
pursuant to Section 15.1 of this Agreement with respect to a country in the Territory, Licensee will have a non-exclusive, fully paid, perpetual, royalty-free right and license under the Licensed Technology to develop, make, have made, use, offer to
sell, sell, and import Products in such country. 
  
 16.4
Survival. In the event of expiration or termination of this Agreement pursuant to Section 15 of this Agreement, the following sections will survive, together with the definitions of any defined terms used therein: Sections 6.3, 8.3, 9.4, 9.5,
9.6, 9.7, 10.3, 10.7, 11.3, 12, 13, 14, 16, 17 and 18. All other provisions, including all rights and obligations thereunder, will terminate and be of no further force and effect. 
  
 17. DISPUTE RESOLUTION 
  
 17.1 The Parties will try to settle their differences amicably between themselves. Subject to Section 2.4 of this
Agreement, in the event of any controversy or claim arising out of or relating to any provision of this Agreement or the performance or alleged non-performance of a Party of its obligations under this Agreement (“Dispute”), a Party
may notify the other Party in writing of such Dispute. If the Parties are unable to resolve the Dispute within 20 days of receipt of the written notice by the other Party, such dispute will be referred to the Chief Executive Officers of each of the
Parties (or their respective designees) who will use their good faith efforts to resolve the Dispute within 15 days after it was referred to the Chief Executive Officers. 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 35 

 17.2 Subject to Section 16.1 of this Agreement, any Dispute that is not resolved as provided in
the preceding Section 17.1, whether before or after termination of this Agreement, will be resolved by in the courts of law located in Raleigh, North Carolina, USA, and each Party hereby irrevocably submits to the jurisdiction and venue of each such
court. 
  
 18. MISCELLANEOUS 

 
 18.1 Patents and Trademarks. Any dispute, controversy or claim
between the Parties relating to the scope, validity, enforceability or infringement of any Patent licensed under this Agreement or of any trademark rights related to a Product will be submitted to a court of competent jurisdiction in the territory
in which such Patent or trademark rights were granted or arose. 
  
 18.2 Further Assurances. At any time during the term of this Agreement, Licensee and POZEN each will, at the request of the other Party, use reasonable efforts to (a) deliver to the other Party such records, data or other documents
consistent with the provisions of this Agreement, (b) execute, and deliver or cause to be delivered, all such assignments, consents, documents or further instruments of transfer or license, and (c) take or cause to be taken all such other actions,
as a Party may reasonably deem necessary or desirable in order for such Party to obtain the full benefits of this Agreement and the transactions contemplated hereby. 
  
 18.3 Assignment. Neither Party will assign its rights or obligations under this Agreement to any Third Party without
the prior written consent of the other Party; except that either Party may assign such rights and obligations to the surviving entity pursuant to a merger, acquisition or consolidation, or to a Third Party acquiring all or substantially all assets
of a Party. All permitted assignments by either Party of any of its rights under this Agreement will be subject to all of the terms and conditions of this Agreement. All successors, permitted assignees of either Party will be subject to, and will be
bound by, all the terms and conditions of this Agreement. Any purported assignment not permitted under the terms of this Agreement will be null, void, and of no effect. 
  
 18.4 Independent Contractors. The Parties hereto are independent contractors. Nothing contained herein will
constitute either Party the agent of the other Party for any purpose whatsoever, or constitute the Parties as partners or joint venturers. Employees of each Party remain employees of said Party and will be considered at no time agents of or owing a
fiduciary duty to the other Party. Neither Party hereto will have any implied right or authority to assume or create any obligations on behalf of or in the name of the other Party or to bind the other Party to any other contract, agreement or
undertaking with any Third Party. 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 36 

 18.5 Waiver. The failure of either Party to enforce any provision of this Agreement at any time
will not be construed as a present or future waiver of such or any other provision of this Agreement. The express waiver by either Party of any provision or requirement hereunder will not operate as a future waiver of such or any other provision or
requirement and will be effective only if set forth in a written instrument signed by a duly authorized representative of the Party waiving such provision or requirement. 
  
 18.6 Amendment. The Parties hereto may amend, modify or alter any of the provisions of this Agreement, but such
amendment, modification or alteration will be valid and binding on either Party only if made by a written instrument that explicitly refers to this Agreement and that is signed by a duly authorized representative of each Party. 
  
 18.7 Severability. In the event that any provision in this Agreement
is held to be unlawful or invalid in any jurisdiction, the meaning of such provision will be construed to the greatest extent possible so as to render it enforceable. If no such construction can render such provision enforceable, it will be severed.
The remainder of this Agreement will remain in full force and effect, and the Parties will negotiate in good faith a reasonable substitute provision that is valid and enforceable in such jurisdiction. If the Parties are unable to agree on a
substitute provision, and if the unlawful or invalid provision was an essential element of this Agreement without which one of the Parties would not have entered into this Agreement, as evidenced by this Agreement as a whole, then such Party may
terminate this Agreement by written notice to the other Party effective upon receipt. 
  
 18.8 Notice. All notices hereunder must be given in writing and will be deemed given if delivered personally or by facsimile transmission (receipt confirmed), mailed by registered or certified mail (return
receipt requested) with postage prepaid, or sent by express courier service (FedEx or other reputable, internationally recognized courier service), to the Parties at the following addresses (or at such other address for a Party as will be specified
by like notice; provided that notices of a change of address will be effective only upon receipt thereof). 
  

			
	 If to POZEN:
	  	 POZEN Inc.

	 	  	 1414 Raleigh Road

	 	  	 Suite 400

	 	  	 Chapel Hill, NC 27517

	 	  	 Attention: President

	 	  	 Telephone: (919) 913 1030

	 	  	 Facsimile: (919) 913 1039

		
	 With copies to:
	  	 Cooley Godward LLP

	 	  	 One Freedom Square

	 	  	 Reston Town Center

	 	  	 11951 Freedom Drive

	 	  	 Reston, VA 20190-5656

	 	  	 Attention:Matthias Alder

	 	  	 Facsimile: (703) 456-8100

  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 37 

			
	 If to Licensee:
	  	 Nycomed Danmark ApS

	 	  	 Langebjerg 1

	 	  	 DK-4000 Roskilde

	 	  	 Denmark

	 	  	 Attention: Managing Director Bent Kjærsgård

	 	  	 Facsimile: +4546756968

		
	 With copies to:
	  	 Nycomed Danmark ApS

	 	  	 Langebjerg 1

	 	  	 DK-4000 Roskilde

	 	  	 Denmark

	 	  	 Attention: General Counsel Theresa Comiskey Olsen

	 	  	 Facsimile: +4766763513

  
 18.9 Force
Majeure. Neither Party will be deemed to be in breach of this Agreement as a result of default, delay or failure to perform by such Party which is due to any cause beyond the reasonable control of such Party, including without limitation, fire,
earthquake, acts of God, severe weather, acts of war, strikes, lockouts or other labor disputes, riots, civil disturbances, actions or inactions of governmental authorities (except actions in response to a breach of applicable laws by such Party),
or epidemics. In the event of any such force majeure, the Party affected will promptly notify the other Party, will use commercially reasonable efforts to overcome such force majeure, and will keep the other Party informed with respect thereto. If
such force majeure continues for a period of more than 180 days, the Party not subject to such force majeure may terminate this Agreement by written notice to the other Party. 
  
 18.10 Counterparts. This Agreement may be executed by the Parties in one or more identical counterparts, all of which
together will constitute this Agreement. If this Agreement is executed in counterparts, no signatory hereto will be bound until both Parties have duly executed a counterpart of this Agreement. 
  
 18.11 Governing Law. This Agreement will be governed by, and construed
an interpreted in accordance with, the laws of the State of North Carolina without giving effect to any choice of law rule that would cause the application of the laws of any jurisdiction other than the internal laws of the State of North Carolina
to the right and duties of the Parties. 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 38 

 18.12 Construction. Unless used in combination with the word “either,” the word
“or” is used throughout this Agreement in the inclusive sense (and/or). The captions of this Agreement are for convenience of reference only and in no way define, describe, extend or limit the scope or intent of this Agreement or the
intent of any provision contained in this Agreement. The term “including” as used herein will mean including, without limiting the generality of any description preceding such term. No rule of strict construction will be applied against
either Party hereto. Unless expressly provided herein to the contrary, all time limits, notice periods, deadlines or the like described herein will be governed by the follow parameters: (i) for all time periods that are 5 days in length or less,
such periods will be deemed to be business days, and (ii) for all time periods greater than 5 days in length will be deemed to be calendar days. 
  
 18.13 English Language. This Agreement has been written and executed in the English language. Any translation into any other language will not be
an official version of this Agreement, and in the event of any conflict in interpretation between the English version and such translation, the English version will control. 
  
 18.14 Entire Agreement. This Agreement, including any Exhibits attached hereto, constitutes the entire agreement of
the Parties with respect to the subject matter hereof, and supersedes all prior and contemporaneous agreements, understandings and negotiations, whether oral or written, with respect to such subject matter, including, without limitation, the
Confidential Disclosure Agreement between the Parties dated [***]; provided, however, that no agreement between the Parties executed contemporaneously with this Agreement (including the Supply Agreement) will be so superseded by
this Agreement. 
  
 [REMAINDER OF
PAGE INTENTIONALLY LEFT BLANK. SIGNATURE PAGE FOLLOWS.] 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 39 

 The Parties have caused this Agreement to be executed as of the Effective Date by signature of their duly authorized
representatives. 
  

	
	POZEN INC.
	  

	 John R. Plachetka

	
	 President and Chief Executive Officer

	
	NYCOMED DANMARK APS
	  

	 Håkan Björklund

	
	 Chief Executive Officer, Nycomed Group

	  

	 Bent Kjærsgård

	
	 Managing Director, Nycomed Danmark ApS

  
 [SIGNATURE PAGE TO THE LICENSE AGREEMENT] 

 EXHIBIT A 
  
 [***] [ENTIRE PAGE REDACTED] 
  

 44 

 EXHIBIT B 
  
 ADDITIONAL MILESTONES UPON RECEIPT OF

 MARKETING APPROVAL IN UK [***] 
  
 If the POZEN MAA receives approval in the United Kingdom on or before the
[***], then Licensee will make the following payments to POZEN in the amounts set forth below within 15 days of the occurrence of the following events: 
  

			
	 MILESTONE EVENT

	  	MILESTONE PAYMENT

	(1) Approval of the POZEN MAA in the United Kingdom	  	[***]$[***]
		
	(2) Receipt of Marketing Approval for a Product in Norway pursuant to the MRP, unless such receipt (a) occurs [***], and (b) was delayed in substantial part by one or more [***] raised by the
regulatory authorities of such country	  	[***]$[***]
		
	(3) Receipt of Marketing Approval for a Product in Finland pursuant to the MRP, unless such receipt (a) occurs [***], and (b) was delayed in substantial part by one or more [***] raised by the
regulatory authorities of such country	  	[***]$[***]
		
	(4) Receipt of Marketing Approval for a Product in Denmark pursuant to the MRP, unless such receipt (a) occurs [***], and (b) was delayed in substantial part by one or more [***] raised by the
regulatory authorities of such country	  	[***]$[***]
		
	(5) Receipt of Marketing Approval for a Product in Sweden pursuant to the MRP, unless such receipt (a) occurs [***], and (b) was delayed in substantial part by one or more [***] raised by the
regulatory authorities of such country	  	[***]$[***]

  
 CONFIDENTIAL TREATMENT HAS BEEN
GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

  

 45 

 EXHIBIT C 
  
 ADDITIONAL MILESTONES UPON RECEIPT OF
MARKETING APPROVAL IN UK 
 [***] OTHER THAN
FOR [***] 
  
 If the POZEN MAA receives
approval in the United Kingdom [***] and such approval was not delayed in substantial part by one or more [***] raised by the MCA, then Licensee will make the following payments to POZEN in the amounts set forth below within 15 days of the
occurrence of the following events: 
  

			
	 MILESTONE EVENT

	  	MILESTONE PAYMENT

	(1) Approval of the POZEN MAA in the United Kingdom	  	[***]$[***]
		
	(2) Receipt of Marketing Approval for a Product in Norway pursuant to the MRP, unless such receipt (a) occurs after the later of (i) [***], and (ii) [***] after the date of approval of the POZEN
MAA in the United Kingdom; and (b) was delayed in substantial part by one or more [***] raised by the regulatory authorities of such country	  	[***]$[***]
		
	(3) Receipt of Marketing Approval for a Product in Finland pursuant to the MRP, unless such receipt (a) occurs after the later of (i) [***], and (ii) [***] after the date of approval of the
POZEN MAA in the United Kingdom; and (b) was delayed in substantial part by one or more [***] raised by the regulatory authorities of such country	  	[***]$[***]
		
	(4) Receipt of Marketing Approval for a Product in Denmark pursuant to the MRP, unless such receipt (a) occurs after the later of (i) [***], and (ii) [***] after the date of approval of the
POZEN MAA in the United Kingdom; and (b) was delayed in substantial part by one or more [***] raised by the regulatory authorities of such country	  	[***]$[***]
		
	(5) Receipt of Marketing Approval for a Product in Sweden pursuant to the MRP, unless such receipt (a) occurs after the later of (i) [***], and (ii) [***] after the date of approval of the POZEN
MAA in the United Kingdom; and (b) was delayed in substantial part by one or more [***] raised by the regulatory authorities of such country	  	[***]$[***]

  
 CONFIDENTIAL TREATMENT HAS BEEN
GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

  

 46 

 EXHIBIT D 
  
 ADDITIONAL MILESTONES UPON RECEIPT OF
MARKETING APPROVAL IN UK 
 [***] FOR [***] 
  
 If the POZEN MAA receives approval in the United Kingdom [***], and such
approval was delayed in substantial part by one or more [***] raised by the MCA, then Licensee will make the following payments to POZEN in the amounts set forth below within 15 days of the occurrence of the following events: 
  

			
	 MILESTONE EVENT

	  	MILESTONE PAYMENT

	(1) Approval of the POZEN MAA in the United Kingdom	  	[***]$[***]
		
	(2) Receipt of Marketing Approval for a Product in Norway pursuant to the MRP, unless such receipt (a) occurs [***], and (b) was delayed in substantial part by one or more [***] raised by the
regulatory authorities of such country	  	[***]$[***]
		
	(3) Receipt of Marketing Approval for a Product in Finland pursuant to the MRP, unless such receipt (a) occurs [***], and (b) was delayed in substantial part by one or more [***] raised by the
regulatory authorities of such country	  	[***]$[***]
		
	(4) Receipt of Marketing Approval for a Product in Denmark pursuant to the MRP, unless such receipt (a) occurs [***], and (b) was delayed in substantial part by one or more [***] raised by the
regulatory authorities of such country	  	[***]$[***]
		
	(5) Receipt of Marketing Approval for a Product in Sweden pursuant to the MRP, unless such receipt (a) occurs [***], and (b) was delayed in substantial part by one or more [***] raised by the
regulatory authorities of such country	  	[***]$[***]

  
 CONFIDENTIAL TREATMENT HAS BEEN
GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

  

 47 

 EXHIBIT E 
  
 Withdrawal Fees 
  
 POZEN will pay Licensee a withdrawal fee in the following amounts under the circumstances described in subsection 15.4.3 of this Agreement: 
  

					
	 Withdrawal Event

	 	 Basis of Withdrawal Fee

	 	 Amount of Withdrawal Fee

	 [***]
	 	[***]%[***]	 	[***]$[***]
	 [***]
	 	[***]%[***]	 	[***]$[***]
	 	 	 	 	[***]$[***]
	 [***]
	 	[***]%[***]	 	[***]$[***]
	 	 	 	 	[***]$[***]
	 [***]
	 	[***]%[***]	 	[***]$[***]
	 	 	 	 	[***]$[***]
	 [***]
	 	[***]%[***]	 	[***]$[***]
	 	 	 	 	[***]$[***]

  
 CONFIDENTIAL TREATMENT HAS BEEN
GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

  

 48 

 EXHIBIT F 
  
 CALCULATION OF MINIMUM ROYALTY AMOUNTS

  
 For each Product and each country in the Territory, the “Minimum
Royalty Amount” is equal to the product obtained by multiplying (i) the number of Units of such Product included in the calculation of Net Sales for such Product in such country, and (ii) the amount set forth on the following table
corresponding to such Product and such country: 
  

					
	 PRODUCT

	 	 COUNTRY

	 	 PER UNIT MINIMUM

	Initial Product	 	All countries of the Territory	 	[***]$[***]

  
 Notwithstanding the foregoing, during
such time as (a) [***]; or (b) [***]; then there will be no Minimum Royalty Amount with respect to sales of such Product in such country; provided, however, that the continuation of one or more of the preceding conditions with respect
to such Product in such country will be reasonably demonstrated by Licensee and reviewed by POZEN. 
  
 For making the comparison described in subsection 9.3.1 of this Agreement, each Per Unit Minimum set forth in the preceding table will be converted into the currency in which Net Sales accrued in such country,
according to the applicable exchange rate as published in The Wall Street Journal, Eastern Edition, on the last business day of the applicable calendar quarter. 
  
 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS AND BRACKETS ([***]). A
COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 49 

 EXHIBIT G 
  
 SUPPLY AGREEMENT 

 POZEN INC./NYCOMED DANMARK APS 
  
 EXHIBIT G 
  
 SUPPLY AGREEMENT 
  

					
	 ARTICLE 1
	  	        DEFINITIONS	  	1
			
	 ARTICLE 2
	  	        COORDINATORS	  	3
			
	 ARTICLE 3
	  	        SALE AND PURCHASE OF PRODUCT	  	3
			
	 ARTICLE 4
	  	        EQUIPMENT; ARTWORK	  	3
			
	                 4.1
	  	Specialized Equipment	  	3
			
	                 4.2
	  	Other Equipment	  	4
			
	                 4.3
	  	Artwork	  	4
			
	 ARTICLE 5
	  	        WARRANTIES; SPECIFICATIONS; QUALITY AGREEMENT	  	5
			
	                 5.1
	  	Warranties by POZEN	  	5
			
	                 5.2
	  	Disclaimer	  	5
			
	                 5.3
	  	Changes to Specifications	  	5
			
	                 5.4
	  	Quality Agreement	  	5
			
	                 5.5
	  	Warranty by Nycomed	  	5
			
	 ARTICLE 6
	  	        FORECASTS; ORDERS	  	6
			
	                 6.1
	  	Forecast Schedules	  	6
			
	                 6.2
	  	Forecast Variances	  	6
			
	 ARTICLE 7
	  	        PURCHASE OF PRODUCT; DELIVERIES	  	6
			
	                 7.1
	  	Purchase Orders	  	6
			
	                 7.2
	  	Purchase Quantities	  	6
			
	                 7.3
	  	Delivery Terms	  	7
			
	                 7.4
	  	Export Compliance	  	7

  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 i 

					
			
	 ARTICLE 8
	  	        PRICE; PRICE INCREASES; ADDITIONAL PAYMENTS	  	7
			
	                 8.1
	  	Price	  	7
			
	                 8.2
	  	Price Increases	  	7
			
	                 8.3
	  	Taxes	  	7
			
	                 8.4
	  	Method of Payment	  	7
			
	 ARTICLE 9
	  	        MANUFACTURING AUDITS; CORRESPONDENCE; COMPLAINTS; RECORDS; INSPECTIONS	  	8
			
	                 9.1
	  	Manufacturing Audits	  	8
			
	                 9.2
	  	Correspondence	  	8
			
	                 9.3
	  	Complaints	  	8
			
	                 9.4
	  	Documentation	  	8
			
	                 9.5
	  	Inspections	  	8
			
	 ARTICLE 10
	  	        RECALLS	  	8
			
	 ARTICLE 11
	  	        REGULATORY	  	9
			
	 ARTICLE 12
	  	        SECOND SOURCE	  	9
			
	 ARTICLE 13
	  	        TERM; TERMINATION	  	9
			
	                 13.1
	  	Term	  	9
			
	                 13.2
	  	Termination by Mutual Agreement	  	9
			
	                 13.3
	  	Termination for Default	  	9
			
	                 13.4
	  	Bankruptcy; Insolvency	  	10
			
	                 13.5
	  	Termination of Other Agreements	  	10
			
	                 13.6
	  	Expiration; Termination; Consequences	  	10
			
	 ARTICLE 14
	  	        CLAIMS	  	11
			
	                 14.1
	  	Claims	  	11
			
	                 14.2
	  	Disposition of Nonconforming Product	  	12
			
	                 14.3
	  	Product Holds/Rejects	  	12

  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 ii 

					
			
	 ARTICLE 15
	  	        INDEMNIFICATION	  	12
			
	                 15.1
	  	Indemnification by Nycomed	  	12
			
	                 15.2
	  	Indemnification by POZEN	  	12
			
	                 15.3
	  	Indemnification Procedures	  	13
			
	                 15.4
	  	Limitation of Liability and Claims	  	13
			
	                 15.5
	  	Insurance	  	13
			
	 ARTICLE 16
	  	        CONFIDENTIALITY	  	14
			
	                 16.1
	  	Confidential Information	  	14
			
	                 16.2
	  	Treatment of Confidential Information	  	14
			
	                 16.3
	  	Access	  	14
			
	                 16.4
	  	Permitted Disclosures	  	14
			
	                 16.5
	  	Return of Confidential Information	  	15
			
	                 16.6
	  	Confidentiality of the Agreement Terms	  	15
			
	 ARTICLE 17
	  	        INTELLECTUAL PROPERTY	  	15
			
	 ARTICLE 18
	  	FORCE MAJEURE	  	16
			
	                 18.1
	  	Effects of Force Majeure	  	16
			
	                 18.2
	  	Notice of Force Majeure Event	  	16
			
	 ARTICLE 19
	  	        LEGAL COMPLIANCE; AUTHORIZATION	  	17
			
	                 19.1
	  	Legal Compliance	  	17
			
	                 19.2
	  	Authorization	  	17
			
	 ARTICLE 20
	  	        DISPUTE RESOLUTION; VENUE	  	17
			
	                 20.1
	  	Exclusions	  	17
			
	                 20.2
	  	Dispute Resolution	  	17
			
	                 20.3
	  	Venue	  	17
			
	 ARTICLE 21
	  	        MISCELLANEOUS	  	18

  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 iii 

 SUPPLY AGREEMENT 
  

THIS SUPPLY AGREEMENT is made effective as of this 30th day of June, 2003 (the “Effective Date”), by and between POZEN INC.
(“POZEN”), a corporation organized under the laws of the State of Delaware and having a place of business at 1414 Raleigh Road, Suite 400, Chapel Hill, NC 27517 and NYCOMED DANMARK
APS (“Nycomed”), a corporation organized under the laws of Denmark and having a place of business at Langebjerg 1, DK-4000 Roskilde, Denmark (each individually a “Party” and
collectively the “Parties”). 
  
 RECITALS 
  
 A. The Parties
have entered into that certain License Agreement dated as of the Effective Date (the “License Agreement”) regarding POZEN’s MT 100 drug product, under which agreement Nycomed receives certain rights to market and sell,
itself or through its Affiliates, such product in finished dosage form for human use; 
  
 B. POZEN has entered into that certain Supply Agreement dated as of January 17, 2001 (the “DSM Supply Agreement”) with DSM Pharmaceuticals (“DSM”), formerly known
as Catalytica Pharmaceuticals, Inc., under which DSM provides POZEN with certain manufacturing, packaging, analytical testing and quality assurance services for the manufacturing, labeling and packaging of MT100 for commercial sale; and 

 
 C. Nycomed desires for POZEN to obtain and sell such product to
Nycomed, and POZEN desires to obtain and sell such product to Nycomed, all on the terms and conditions set forth in this Agreement; 
  
 NOW, THEREFORE, in consideration of the mutual covenants and promises set forth herein and other good
and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows: 
  
 ARTICLE 1 
  
 DEFINITIONS 
  
 The following terms, whether used in the singular or plural, shall have the meanings assigned to them below for purposes of this Agreement: 
  
 1.1 “Affiliate” shall mean a corporation or other business entity that, directly or indirectly, through one or more
intermediaries, controls, is controlled by, or is under common control with a Party. For purposes of this definition only, “control” and, with corresponding meanings, the terms “controlled by” and “under common control
with” means (a) the possession, 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 1 

 directly or indirectly, of the power to direct the management or policies of a legal entity, whether through the
ownership of voting securities or by contract relating to voting rights or corporate governance, or (b) the ownership, directly or indirectly, of more than 50% of the voting securities or other ownership interest of a legal entity; provided,
however, that if local law restricts foreign ownership, control shall be established by direct or indirect ownership of the maximum ownership percentage that may, under such local law, be owned by foreign interests. 
  
 1.2 “Batch” shall mean [***] Units of Product,
or such other number of Units of Product as may be agreed upon by the Parties and DSM. 
  
 1.3 “Confidential Information” shall have the meaning set forth in Section 16.1. 
  
 1.4 “Contract Year” shall mean the period of twelve (12) successive calendar months commencing on the first day of the
month of the first Delivery Date, and each successive twelve (12) month period thereafter. Nycomed shall confirm in writing to POZEN the commencement of the first Contract Year promptly after the occurrence thereof. 
  
 1.5 “Delivery Date” shall mean a date for
which delivery of Product is stated in a purchase order submitted by Nycomed to POZEN hereunder. 
  
 1.6 “FD&C Act” shall mean the United States Federal Food, Drug and Cosmetic Act, as amended. 
  
 1.7 “FDA” shall mean the United States Food
and Drug Administration, or any successor entity. 
  
 1.8
“License Agreement” shall mean that certain License Agreement between POZEN and Nycomed dated as of the Effective Date. 
  
 1.9 “MAA” shall mean a Marketing Authorization Application submitted to the appropriate regulatory body in a European
country (including Norway) for the purposes of obtaining approval for the marketing of a prescription pharmaceutical product in such country. 
  
 1.10 “POZEN MAA” shall mean MAA [***] submitted to the United Kingdom Medicines Control Agency on October 8, 2002, [***],
to obtain approval for the marketing of the Product in the United Kingdom. 
  
 1.11 “Product” shall mean an oral formulation of POZEN’s MT 100 drug product containing [***] naproxen sodium and [***] metoclopramide hydrochloride in tablet form, conforming to
the Specifications. 
  
 1.12 “Product
Approval” shall mean approval of an MAA for the Product in a country of the Territory. 
  
 1.13 “Product Price” shall mean the applicable price per Unit of Product [***]. The initial Product Price for each Unit of
Product is set forth in Exhibit 1 attached hereto and made a part hereof, as such exhibit may be amended from time to time during the Term in accordance with the terms of this Agreement. 
  
 1.14 “Quality Agreement” shall have the meaning set forth in Section 5.4. 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 2 

 1.15 “Specifications” shall mean the specifications for the Product
attached hereto as Exhibit 2 and made a part hereof, as determined in accordance with the analytical methodology set forth therein, as such specifications may be amended from time to time by mutual agreement of the Parties, including without
limitation such amendments as may be required to obtain Product Approval. 
  
 1.16 “Term” shall have the meaning set forth in Section 13.1 hereof. 
  
 1.17 “Territory” shall mean Denmark, Finland, Norway, and Sweden. 
  
 1.18 “Third Party” shall mean any individual
or entity other than Nycomed, POZEN and their respective Affiliates. 
  
 1.19 “Unit” shall mean a single tablet of Product. 
  
 ARTICLE 2 
  
 COORDINATORS 
  
 Within ten (10) days after the
date hereof, Nycomed and POZEN shall each appoint an authorized representative and a backup representative for the exchange of all communications, other than legal notices, related to the manufacturing of the Product. Each Party shall provide notice
to the other Party as to the name and title of the individuals so appointed. Each Party may replace its representatives at any time for any reason by providing written notice to the other Party in accordance with Section 21.9 hereof. 
  
 ARTICLE 3 
  
 SALE AND PURCHASE OF PRODUCT 
  
 During each Contract Year throughout the Term, and subject to the provisions
herein, POZEN agrees to sell to Nycomed and Nycomed agrees to purchase from POZEN, Nycomed’s and its Affiliates’ [***] for sale in the Territory. Notwithstanding the provision above, Nycomed will be entitled during the Term to[***]
provided, however, that, except as expressly provided in this Agreement, Nycomed will have [***]. However, notwithstanding anything to the contrary in this provision, during the [***] immediately preceding the [***] Nycomed shall have
the right to[***]. 
  
 Nycomed understands and agrees that, [***]
under this Agreement[***], either (a)[***] or (b) [***] under this Agreement [***]. 
  
 ARTICLE 4 
  
 EQUIPMENT;
ARTWORK 
  
 4.1 Specialized Equipment. 
  
 (a) Acquisition. [***] shall [***] for all [***] and [***] associated
with the purchase, lease, installation and qualification by DSM of any equipment, [***] or [***] that is 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 3 

 required by [***] for the sole purpose of [***] for sale in the Territory and the [***] of which is approved in writing
by [***] prior to [***] (collectively, the “Specialized Equipment”) within [***] therefor. Prior to requesting Nycomed’s approval of the acquisition or lease of Specialized Equipment, POZEN [***]. Any [***] related to
[***] shall be handled in a similar manner as outlined in this Section 4.1. 
  
 (b) Maintenance. [***] shall be responsible for the [***] and the [***] of [***] and [***] of the Specialized Equipment during the Term. [***] shall be responsible for the [***] of the Specialized Equipment
(including, by way of example, any [***] [***] shall notify [***] prior to the [***] of any such [***] and [***] shall [***] for any such [***] or [***] has authorized to be [***]. 
  
 (c) Transfer. Upon any expiration or termination of this Agreement [***], at Nycomed’s option: (i) the Parties
shall promptly agree on a procedure whereby Nycomed shall obtain possession of the Specialized Equipment with [***], or (ii) with POZEN’s approval, [***] of such Specialized Equipment. 
  
 4.2 Other Equipment. 
  
 (a) Notice. As between the Parties, POZEN will be responsible for
coordinating the acquisition and maintenance by DSM of any equipment that is required for obtaining or maintaining approval of the POZEN MAA in the United Kingdom and that is acquired after the Effective Date. POZEN will give Nycomed [***] written
notice in the event that DSM and POZEN agree that such acquisition or maintenance is required (each such notice, an “Equipment Notice”). POZEN will set forth in each Equipment Notice a description of [***]. 
  
 (b) Consent by [***]. Upon [***] written consent, not to be
unreasonably withheld [***],[***] will be responsible for the [***]; provided, however, that Nycomed [***], as defined below. For the purposes of this Section 4.2 only, [***] means a [***]. 
  
 (c) Disputes. If [***] does not give its consent pursuant to the
foregoing Section 4.2(b) to [***], then the Parties will meet to discuss the issue. If the Parties are not able to agree upon a resolution of such issue, including an inability to reach agreement by the designated officers pursuant to Section 20.2
despite good faith efforts by the Parties, then [***]. If [***]. If [***]. 
  
 4.3 Artwork. At least [***] prior to (a) the first Delivery Date or (b) any modification to the artwork for the Product, as applicable, and from time to time thereafter with respect to the Product, as needed,
Nycomed shall provide [***] to POZEN, in a format acceptable to both Parties and in a timely manner, digital artwork for all packaging components to be used in the manufacture of the Product, which artwork shall meet the applicable Specifications
[***]. 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 4 

 ARTICLE 5 
  

WARRANTIES; SPECIFICATIONS; QUALITY AGREEMENT 
  
 5.1 Warranties by POZEN. POZEN warrants to Nycomed that Product, on delivery, (a) shall conform to the Specifications, as then in effect; (b) shall
have been manufactured in accordance with (i) then-current good manufacturing practices as set forth in the “Rules Governing Medicinal Products in The European Community – Volume IV Good Manufacturing Practice for Medicinal Products”
(“cGMPs”), and (ii) the [***] and (c) shall not be adulterated or misbranded within the meaning of the FD&C Act, or an article that may not be introduced into interstate commerce under the provisions of Sections 404 or 505 of
the FD&C Act. 
  
 5.2 Disclaimer. EXCEPT AS OTHERWISE
EXPRESSLY PROVIDED IN SECTION 5.1 ABOVE OR IN THE LICENSE AGREEMENT, POZEN MAKES NO WARRANTY THAT THE PRODUCT (i) [***] (ii) [***], OR (iii)[***]; NOR DOES POZEN MAKE ANY OTHER WARRANTIES WITH RESPECT TO THE PRODUCT, EXPRESS OR IMPLIED, EXCEPT AS
EXPRESSLY STATED IN THIS AGREEMENT OR IN THE LICENSE AGREEMENT. 
  
 5.3 Changes to Specifications. In the event Nycomed desires to change the Specifications or the manufacturing process for Product (including without limitation to achieve compliance with regulatory requirements from authorities in
the Territory), Nycomed shall promptly advise POZEN in writing of such desired changes, and [***] such changes. POZEN shall promptly advise Nycomed as to any [***]. Prior to implementation of such changes, POZEN shall inform Nycomed of (a) [***],
and (b) [***] due to a change in Specifications, including an inability to reach agreement by the designated officers pursuant to Section 20.2 despite good faith efforts by the Parties, then POZEN shall [***] If [***] If [***]. If, during the Term,
Nycomed amends or is required by law to amend the Specifications so as to render certain materials or components for the Product obsolete, [***] as the result of the obsolescence of any Product-specific inventory of materials, packaging components,
or Product reasonably [***] to satisfy existing purchase orders or forecasted requirements, to the extent that the relevant items are not sold to Third Parties or are not used in [***]. 
  
 5.4 Quality Agreement. Within three (3) months following the Effective Date, the Parties will enter into an agreement
describing the quality assurance obligations and responsibilities of the Parties with respect to the manufacture and supply of Product under this Agreement (the “Quality Agreement”). Under
the Quality Agreement, Nycomed will undertake, at a minimum, [***]. Notwithstanding anything to the contrary in this Agreement or in any other document or agreement, in the event of a conflict between this Agreement and the Quality Agreement, this
Agreement shall govern and control. 
  
 5.5 Warranty by
Nycomed. Subject to Section 5.1, Nycomed hereby represents and warrants to POZEN that it will comply fully with all export administration and control laws and regulations as may be applicable to the export, resale or other disposition of any
Product purchased by Nycomed hereunder. 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 5 

 ARTICLE 6 
  

FORECASTS; ORDERS 
  
 6.1 Forecast Schedules. 
  
 (a) Long-Term Forecast Schedule. [***] prior to estimated Product Approval, Nycomed shall deliver to POZEN a forecast of Nycomed’s Unit
requirements for Product for each calendar year during the Term. Such forecast shall thereafter be updated as required by Nycomed, but at least [***] during the Term. 
  
 (b) Detailed Forecast Schedule. At least [***] prior to the first anticipated Delivery Date, Nycomed shall deliver to
POZEN a detailed forecast of Nycomed’s Unit requirements for Product for each month during the first Contract Year. Such detailed forecast shall thereafter be updated [***] so that[***], POZEN shall have been provided with a rolling detailed
forecast for each [***] after the date on which such forecast is submitted. The forecast for the first [***] contained in each such detailed forecast shall be firm and binding on Nycomed and POZEN. Subsequent purchase orders shall be accepted by
POZEN provided that the forecast for each of the [***] has varied from the relevant forecast submitted in the previous [***] pursuant to this subsection 6.1(b) by no more than [***] percent ([***]%). Notwithstanding the preceding sentence, POZEN
shall accept purchase orders for a quantity of Product during the [***] of the first Contract Year which vary from the applicable and otherwise binding forecast by up to [***] percent ([***]%). 
  
 6.2 Forecast Variances. In addition to the obligation to supply
Nycomed within the [***] set forth in Section [***]. 
  
 ARTICLE
7 
  
 PURCHASE OF PRODUCT; DELIVERIES 
  
 7.1 Purchase Orders. Except to the extent the Parties may otherwise
agree with respect to a particular shipment, Product shall be ordered by Nycomed pursuant to written purchase orders, which shall be sent to POZEN with [***] prior to the Delivery Dates specified in such purchase orders. Upon receipt of each
purchase order by POZEN hereunder, POZEN shall [***]. 
  
 7.2
Purchase Quantities. Nycomed shall order Product hereunder in Batch sizes or whole multiples thereof. Each purchase order submitted by Nycomed hereunder shall specify the quantity of Units of Product being ordered. Notwithstanding anything in
this Agreement to the contrary, [***]; provided, however, Nycomed shall only be [***]; and provided, further, that POZEN shall [***]. 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 6 

 7.3 Delivery Terms. The terms of delivery for the Product shall be [***] DSM’s Greenville, NC
plant. Title and risk of loss and/or damage to Product shall pass to Nycomed upon delivery of such Product [***] at DSM’s Greenville, NC plant. 
  
 7.4 Export Compliance. Nycomed shall prepare, obtain, and maintain all necessary import and export registrations relating to the Product. Nycomed
represents and warrants that it shall comply with all import and export laws and regulations applicable to its purchase of Product hereunder. 
  
 ARTICLE 8 
  
 PRICE; PRICE INCREASES; ADDITIONAL PAYMENTS 
  
 8.1 Price. For all Product delivered to Nycomed pursuant to this Agreement, Nycomed shall pay to POZEN: (a) [***]% [***], and (b) [***]% [***], in
each case subject to adjustment as set forth in Sections 5.3 and 8.2 hereof. 
  
 8.2 Price Increases. 
  
 (a) Nycomed understands and agrees that, [***] (i) [***] (ii) [***], and (iii)[***]. POZEN hereby represents and warrants that, as of the Effective Date,[***]. POZEN shall inform Nycomed if POZEN [***]. 
  
 (b) Notwithstanding the prices set forth in Section 8.1 above, the
[***] pursuant to this Agreement [***]% [***] later of: (i) [***], and (ii) [***]. 
  
 8.3 Taxes. The Product Price set forth in Exhibit 1 does not include[***]. POZEN shall add the amount of such taxes, if any, to the purchase price of Product in effect at the time of shipment thereof and
include such amount in the invoices submitted to Nycomed by POZEN hereunder. Nycomed shall pay the amount of such taxes to POZEN in accordance with the payment provisions of this Agreement. 
  
 8.4 Method of Payment. At the time of each shipment of Product
hereunder, POZEN shall invoice Nycomed, and Nycomed shall pay for such Product [***] of receipt of each such invoice. All payments due hereunder to POZEN shall be sent to POZEN at the times set forth herein by wire transfer of funds to such account
of POZEN as POZEN may designate to Nycomed in writing from time to time in accordance with Section 21.9 hereof. Nycomed shall notify such person as POZEN may designate to Nycomed from time to time in accordance with Section 21.9 hereof as to the
making of all payments hereunder. All amounts not paid when due shall bear interest from the due date at the rate of [***] percent ([***]%) per month (or such other percentage, if lower, as shall not exceed the maximum rate permitted by law). In
addition to any other rights POZEN may have, if any undisputed amount remains outstanding for more than [***]. 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 7 

 ARTICLE 9 
  

MANUFACTURING AUDITS; CORRESPONDENCE; 
 COMPLAINTS; RECORDS; INSPECTIONS 
  
 9.1
Manufacturing Audits. 
  
 (a) Scheduled Audit. Upon
request by Nycomed, POZEN will [***]. 
  
 (b) Triggered
Audits. Nycomed shall be entitled to request [***] in the event of: (i) [***] (ii) [***] or (iii) [***]. As promptly as practicable following [***]. Nycomed shall [***]. 
  
 9.2 Correspondence. Each Party shall promptly notify the other Party of, and shall provide such other Party with
copies of, any correspondence and other documentation received or prepared by the notifying Party in connection with any of the following events: (a) [***] (b) [***] and (c) [***] Furthermore, Nycomed shall promptly provide POZEN with a copy of any
[***]. POZEN will use commercially reasonable efforts to [***]. 
  
 9.3 Complaints. Nycomed and POZEN shall each maintain complaint files with respect to the Product in accordance with cGMPs. Each Party shall provide the other Party with copies of all complaints received by it [***] with respect to
the Product within the time periods specified in the Quality Agreement, as well as copies of any responses to complaints relating to the manufacture of the Product. As between the Parties, [***], including, but not limited to, complaints relating to
the manufacture of the Product as well as adverse drug events (ADE) reports. As between the Parties, [***], including, but not limited to, complaints relating to the manufacture of the Product as well as adverse drug events (ADE) reports. POZEN will
use commercially reasonable efforts to [***]. 
  
 9.4
Documentation. POZEN shall furnish to Nycomed with each invoice for Product ordered by Nycomed hereunder a copy of DSM’s certificate of analysis reflecting that such Product meets the Specifications, [***]. 
  
 9.5 Inspections. Should POZEN receive notice [***] In the event POZEN
receives notice [***], including, but not limited to, [***]. 
  
 ARTICLE 10 
  
 RECALLS 
  
 POZEN and Nycomed each shall notify the other promptly if any shipment of
Product is alleged or proven to be the subject of a recall, market withdrawal or correction, and the Parties shall cooperate in the handling and disposition of such recall, market withdrawal or correction; provided, however, in the event of a
disagreement as to any matters related to such recall, market withdrawal or correction, [***] as set forth in the immediately following sentence, [***] shall [***] of all recalls, market withdrawals or corrections of Product within the Territory
except to the extent such recall, market withdrawal or correction shall have been the result of [***] of administering such recall, market withdrawal or correction and substantiation; provided, 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 8 

 however, in no event shall [***] under this Article 10 [***] of administering such recall, market withdrawal or
correction and substantiation (if applicable) for the Product subject to such recall, including but not limited to,[***]. Nycomed shall maintain records of all sales of Product and customers sufficient to adequately administer a recall, market
withdrawal or correction for a period of after termination or expiration of this Agreement. Nycomed, with the reasonable cooperation of POZEN, shall in all events be responsible for conducting any recalls, market withdrawals or corrections with
respect to the Product within the Territory. 
  
 ARTICLE 11

  
 REGULATORY 
  
 The responsibilities of the Parties with respect to maintaining the Product
Approvals are set forth in the License Agreement. 
  
 ARTICLE 12

  
 SECOND SOURCE 
  
 Nycomed shall, reasonably in advance of any anticipated termination or
expiration of this Agreement, establish an independent source of supply or engage a third party supplier to provide commercial quantities of Product commencing upon the effective date of such termination or expiration. Upon request by Nycomed, POZEN
shall (a) [***], (b) [***], (c) [***], and (d) [***]. Reasonably in advance of entering into any commitment for such independent source, Nycomed will [***]. 
  
 ARTICLE 13 
  
 TERM; TERMINATION 
  
 13.1 Term. Unless sooner terminated pursuant to the terms hereof, the term of this Agreement (the “Term”) shall commence on
the Effective Date and shall continue until the third anniversary of the first commercial sale of the Product anywhere in the world following final approval by the FDA of POZEN’s new drug application for the Product. POZEN shall provide Nycomed
with prompt written notice of the first commercial sale of the Product anywhere in the world by POZEN, its Affiliates or licensees following final approval by the FDA of POZEN’s new drug application for the Product. 
  
 13.2 Termination by Mutual Agreement. This Agreement may be terminated
at any time upon mutual written agreement between the Parties. 
  
 13.3 Termination for Default. This Agreement may be terminated by either Party in the event of the material breach or default by the other Party of the terms and conditions hereof; provided, however, the other Party shall first give
to the defaulting Party written notice of the proposed termination or cancellation of this Agreement, specifying the grounds therefor. Upon 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 9 

 receipt of such notice, the defaulting Party shall have [***] to respond by curing such default (or [***] with respect to
a failure by Nycomed to pay any amounts hereunder when due) or by delivering to the other Party a certificate that such breach is not capable of being cured within such [***] and that the breaching Party is working diligently to cure such breach,
but in no event shall the time period for curing such breach exceed an additional [***] unless otherwise mutually agreed by the Parties. If the breaching Party does not so respond or fails to work diligently and to cure such breach within the
additional time set forth above, then the other Party may either suspend the Agreement indefinitely or terminate the Agreement. Notwithstanding the foregoing, if Nycomed has established an alternative source that is approved by the regulatory
authorities in the Territory to supply Product for commercial sale in the Territory, then Nycomed shall have the right to terminate this Agreement immediately upon notice if POZEN fails to deliver in accordance with any of Sections 6.1, 7.1, 7.2 or
7.3 hereof (i) within [***] following any Delivery Date or (ii) on more than [***] occasions, and such default shall be deemed to be a material breach; provided, however, that Nycomed will have no right to terminate this Agreement for such failure
if (a) Nycomed is in material breach under this Agreement at the time of such failure and is not making diligent efforts to cure such breach, or (b) such failure resulted from or is related to a Force Majeure Event (as defined in Section 18.1), or
(c) such failure is directly caused by the acts or omissions of Nycomed. Termination of this Agreement pursuant to this Section 13.3 shall not affect any other rights or remedies which may be available to the nondefaulting Party. 
  
 13.4 Bankruptcy; Insolvency. Either Party may immediately terminate
this Agreement upon the occurrence of either of the following: 
  
 (a) The entry of a decree or order for relief by a court having jurisdiction in the premises in respect of the other Party in an involuntary case under any applicable national, federal, or state insolvency or other similar law and
the continuance of any such decree or order unstayed and in effect for a period of sixty (60) consecutive days; or 
  
 (b) The filing by the other Party of a petition for relief under any applicable national, federal, or state insolvency or other similar law.

  
 13.5 Termination of Other Agreements. This Agreement
shall terminate automatically upon any expiration or termination of the License Agreement or DSM Supply Agreement. 
  
 13.6 Expiration; Termination; Consequences. 
  
 (a) Upon expiration or termination of this Agreement, whichever is sooner, ([***]), POZEN shall use commercially reasonable efforts to [***], and
Nycomed shall purchase in accordance with the provisions hereof, any and all amounts of Product ordered by Nycomed hereunder prior to the date on which such notice is given. 
  
 (b) Upon termination of this Agreement due to the expiration or termination 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 10 

 of the DSM Supply Agreement, Nycomed shall reimburse POZEN for [***] any amounts payable by POZEN to DSM due to
obligations under the DSM Supply Agreement for: (i) [***], (ii) [***], (iii) [***], and (iv) other reasonable commitments. All costs listed under the foregoing (i) through (iv) are payable only to the extent that they are reasonably made [***].

  
 (c) Upon any expiration or termination of this
Agreement, other than termination by Nycomed pursuant to Section 13.3 or 13.4 hereof or termination due to the expiration or termination of the Supply Agreement, Nycomed shall reimburse POZEN for any amounts paid by POZEN to DSM under the Supply
Agreement for: (i) [***], (ii) [***] (iii) [***] (iv) all other reasonable commitments that cannot be cancelled and that were made [***], and (v) any and all [***]. 
  
 (d) Upon any expiration or termination of this Agreement, the obligations set forth in the following provisions of
this Agreement shall survive, together with any definitions used or Exhibits referenced therein: Sections 4.3, 5.1, 5.2, and 13.6, and Articles 12, 15, 16, 20 and 21. 
  
 ARTICLE 14 
  
 CLAIMS 
  
 14.1 Claims. In the event that any of the Product delivered to Nycomed’s designated carrier by POZEN shall fail to conform with any warranty
set forth herein relating to quality and/or the Specifications, Nycomed may reject such Product by giving written notice to both POZEN and DSM within the earlier to occur of (i) [***] of delivery of such Product to Nycomed [***], or (ii) [***] after
receipt of such Product at Nycomed’s designated facility; any Product not rejected in accordance with the foregoing shall be deemed accepted by Nycomed and conforming, provided that appropriate certification documentation is included with
shipment. Any notice given hereunder shall specify the manner in which the Product fails to meet such warranty or the Specifications. If it is determined by agreement of the Parties (or in the absence of agreement of the Parties by a mutually
acceptable independent laboratory or consultant whose fees shall be paid by the non-prevailing Party) that the nonconformity is due to damage to the Product (i) caused by Nycomed or its agents or (ii) which occurs subsequent to delivery of such
Product to[***], POZEN shall have no liability to Nycomed with respect thereto. If the nonconformity in rejected Product is not caused by Nycomed and occurs prior to the delivery to Nycomed or is otherwise caused by negligent acts or omissions or
willful misconduct (including, without limitation, failure to verify that materials supplied by a third party supplier conform to the specifications for such materials) by DSM, POZEN, or their respective Affiliates, then POZEN shall credit
Nycomed’s account for the price invoiced for such nonconforming Product. If payment therefor has previously been made by Nycomed, POZEN shall, at Nycomed’s sole option, (x) pay Nycomed the amount of such credit, (y) offset 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 11 

 the amount thereof against other amounts then due POZEN hereunder or (z) use commercially reasonable efforts to cause DSM
to replace such nonconforming Product with conforming Product at no additional cost to Nycomed. Except as set forth in Section 15.2, the foregoing remedy constitutes the exclusive remedy against POZEN, and the entire liability of POZEN, in
connection with any rejected Product. 
  
 14.2 Disposition of
Nonconforming Product. In any case where Nycomed expects to make a claim against POZEN with respect to damaged or otherwise nonconforming Product, Nycomed shall not dispose of such Product without written authorization and instructions of POZEN
either to dispose of the Product or to return the Product to POZEN. If the Product is returned to POZEN, all risk of loss and/or damage to such Product shall pass to POZEN upon delivery of the Product to POZEN’s designated carrier at
Nycomed’s designated facility. 
  
 14.3 Product
Holds/Rejects. POZEN shall notify Nycomed promptly of Product holds and/or rejects that have, or are expected to have, an impact on the manufacturing process for Product and that shall require, or are expected to require, Nycomed approval prior
to resolution. 
  
 ARTICLE 15 
  
 INDEMNIFICATION 
  
 15.1 Indemnification by Nycomed. Nycomed shall indemnify, defend and
hold POZEN, its Affiliates and their respective directors, officers, employees, agents, successors and assigns harmless from and against any damages, judgments, claims, suits, actions, liabilities, costs and expenses (including, but not limited to,
reasonable attorneys’ fees) to the extent arising out of or connected with (a) the use, handling, distribution, marketing or sale of the Product (except to the extent caused by a material breach by POZEN of any of its representations or
warranties hereunder or by the negligent acts or omissions or willful misconduct (including, without limitation, failure to verify that materials supplied by a Third Party supplier conform to the specifications for such materials) of POZEN or its
Affiliates in the use, manufacture, handling, distribution or labeling of the Product or in the performance of POZEN’s other obligations or duties hereunder); (b) Nycomed’s breach of any of its warranties, representations, covenants or
duties hereunder; or (c) Nycomed’s negligent acts or omissions or willful misconduct. 
  
 15.2 Indemnification by POZEN. Except as otherwise provided in Section 15.1 above, POZEN shall indemnify, defend and hold Nycomed, its Affiliates and their respective directors, officers, employees, agents,
successors and assigns harmless from and against any damages, judgments, claims, suits, actions, liabilities, costs and expenses (including, but not limited to, reasonable attorneys’ fees) to the extent arising out of or connected with: (a)
POZEN’s breach of any of its warranties, representations, covenants, or duties hereunder; (b) 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 12 

 POZEN’s negligent acts or omissions or willful misconduct hereunder; (c) possession of the Specialized Equipment by
DSM at its facilities during the Term, including, without limitation, POZEN’s failure to perform routine maintenance of the Specialized Equipment, misuse by POZEN of the Specialized Equipment, and injury to any person and damage to property
caused by the Specialized Equipment; or (d) DSM’s negligent acts or omissions or willful misconduct, or infringement or misappropriation by DSM of any intellectual property, proprietary rights, or proprietary or confidential information of any
Third Party, in the manufacture, handling, distribution or labeling of the Product, to the extent that POZEN is entitled to indemnification for such losses from DSM under the terms of the DSM Supply Agreement. 
  
 15.3 Indemnification Procedures. A Party (the
“Indemnitee”) which intends to claim indemnification under this Article 15 shall promptly notify the other Party (the “Indemnitor”) in writing of any action, claim or other matter in respect of which
the Indemnitee or any of its Affiliates, or any of their respective directors, officers, employees or agents intend to claim such indemnification; provided, however, the failure to provide such notice within a reasonable period of time shall not
relieve the Indemnitor of any of its obligations hereunder except to the extent the Indemnitor is prejudiced by such failure. The Indemnitee, its Affiliates, and their respective directors, officers, employees and agents shall cooperate fully with
the Indemnitor and its legal representatives in the investigation, negotiation, compromise, settlement and defense of any action, claim or other matter covered by this indemnification. The Indemnitor shall be in charge of and control of any such
investigation, negotiation, compromise, settlement and defense and shall have the right to select counsel with respect thereto, provided that the Indemnitor shall promptly notify the Indemnitee of all developments in the matter. In no event shall
the Indemnitor or Indemnitee compromise or settle any such matter without the prior written consent of the other Party, which shall not be bound by any such compromise or settlement absent its prior consent, which shall not be unreasonably withheld
or delayed. The Indemnitee shall have the right, but not the obligation, to be represented by counsel of its own selection and at its own expense. 
  
 15.4 Limitation of Liability and Claims. In no event shall either Party be liable to the other Party for incidental, special, consequential or
punitive damages, including, but not limited to, any claim for damages based upon lost profits. In addition, in no event shall the collective, aggregate liability of POZEN and its Affiliates and its and their respective directors, officers,
employees and agents under this Agreement exceed $10,000,000 per annum. 
  
 15.5 Insurance. Upon request, Nycomed and POZEN shall provide each other with documentation evidencing the maintenance of product liability and/or general liability insurance coverage in an appropriate amount,
but in any event not less than $[***] insurance coverage by POZEN and not less than $[***] insurance coverage by Nycomed. 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 13 

 ARTICLE 16 
  
 CONFIDENTIALITY 
  
 16.1 Confidential Information. Any information or materials communicated by one Party to the other Party pursuant to this Agreement shall be deemed
“Confidential Information” of the disclosing Party, if such information: (a) is marked “confidential” or with a similar legend, (b) if disclosed orally or visually, is identified as being confidential at the time of
such oral or visual disclosure and is thereafter reduced to writing, marked “confidential” or with a similar legend, and sent to the other Party within 30 days of such oral or visual disclosure, or (c) would, due to the nature thereof or
the circumstances surrounding disclosure, appear to a reasonable person to be confidential or proprietary. Notwithstanding the preceding sentence, “Confidential Information” shall not be deemed to include information that the receiving
Party can demonstrate, by competent written proof: 
  
 (a)
At the time of disclosure is published or is publicly known or otherwise in the public domain, other than through any act or omission by the receiving Party; 
  
 (b) Was already known to the receiving Party, other than under an obligation of confidentiality or non-use, prior to
the time of disclosure; 
  
 (c) Is disclosed to the
receiving Party in good faith, without an obligation of confidentiality, by a Third Party not under any obligation of confidence with respect to such information; or 
  
 (d) Is independently developed by the receiving Party without use of or reference to the disclosing Party’s
Confidential Information. 
  
 16.2 Treatment of Confidential
Information. The Parties agree that during the Term and for 7 years after its expiration or termination for any reason whatsoever, a Party receiving Confidential Information of the other Party shall: (a) treat any such Confidential Information
disclosed to it by the other Party as strictly confidential; (b) except as necessary in the performance of this Agreement, not disclose such Confidential Information to Third Parties without the prior written consent of the other Party, other than
to its Affiliates, licensees, collaborators or any consultants, provided that such disclosure be under confidentiality agreements with provisions comparable to those contained in this Agreement; (c) not use such Confidential Information for purposes
other than those authorized expressly herein; and (d) use reasonable efforts to prevent inadvertent disclosure of such Confidential Information. 
  
 16.3 Access. Access to Confidential Information shall be limited to those employees of the Party receiving such information or of such Party’s
Affiliates who reasonably require such information in order to carry out activities authorized pursuant to this Agreement. Such employees shall be advised of the confidential nature of the Confidential Information and the related confidentiality
undertaking. 
  
 16.4 Permitted Disclosures.
Notwithstanding any other provision in this Agreement, a receiving Party may disclose Confidential Information of the disclosing Party to the extent 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 14 

 such disclosure is required by law or court order, provided that the receiving Party gives the disclosing Party prompt
written notice of the requirement to disclose and reasonably cooperates with the disclosing Party to seek a protective order or other restrictions on the disclosure of such Confidential Information of the disclosing Party. Any such required
disclosure will be limited only to that Confidential Information that is required to be disclosed and such disclosed Confidential Information shall remain Confidential Information hereunder despite the required disclosure. Furthermore, Nycomed or
its Affiliates may disclose Confidential Information of POZEN to government or other regulatory authorities to the extent that such disclosure is legally necessary to obtain authorizations to conduct clinical trials with and to commercialize the
Product. Upon POZEN’s request (made no more frequently than once each calendar year), Nycomed shall, as promptly as reasonably practicable, advise POZEN of the Confidential Information of POZEN provided by Nycomed to such government or other
regulatory authorities since POZEN’s last such request, and the identities of the particular authorities to which Nycomed or its Affiliates have provided such Confidential Information. 
  
 16.5 Return of Confidential Information. Upon termination or
expiration of this Agreement, each Party hereto and its Affiliates shall return all Confidential Information of the other Party in their possession to the other Party; provided, however, that each Party may retain: (a) a single
archival copy of the Confidential Information of the other Party solely for the purpose of determining the extent of disclosure of Confidential Information hereunder and assuring compliance with the surviving provisions of this Agreement; (b) any
portion of the Confidential Information of the other Party which is contained in laboratory notebooks; and (c) any portion of the Confidential Information of the other Party which a Party is required by mandatory applicable law to retain.

  
 16.6 Confidentiality of the Agreement Terms. Neither
Party shall disclose the terms of this Agreement to any Third Party without the prior written consent of the other Party; provided, however, that either Party may disclose the terms of this Agreement to actual or prospective investors
and corporate partners, to a Party’s accountants, attorneys and other professional advisors, and as required by applicable laws and regulations of the U.S. Securities and Exchange Commission and any stock exchange on which a Party’s stock
is traded. 
  
 ARTICLE 17 
  
 INTELLECTUAL PROPERTY 
  
 Nycomed acknowledges that DSM and POZEN possess certain inventions,
processes, know-how, trade secrets, improvements, other intellectual properties and other assets, including but not limited to procedures and techniques, and certain technical expertise and conceptual expertise, which have been independently
developed by DSM, POZEN or their respective Affiliates without the benefit of any information provided by Nycomed (collectively “Reserved  
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 15 

 Property”). Nycomed understands and agrees that all right, title and interest in and to the Reserved
Property will be owned by [***]. Nycomed understands and agrees that any Reserved Property that has been developed or discovered by [***] as described in Article [***]. Nycomed and POZEN agree that the Product or improvements thereto which are used,
improved, modified or developed by POZEN prior to or during the Term and any data directly and specifically relating to the Product generated during the performance of this Agreement are the sole and exclusive property of POZEN and will be
transferred to Nycomed under the terms and conditions set forth in Article 12 above. In no event will the provisions of this Article 17 be construed to limit the rights and licenses granted by POZEN to Nycomed pursuant to the License
Agreement. 
  
 ARTICLE 18 
  
 FORCE MAJEURE 
  
 18.1 Effects of Force Majeure. Neither Party shall be held liable or
responsible for failure or delay in fulfilling or performing any of its obligations under this Agreement in case such failure or delay is due to any condition beyond the reasonable control of the affected Party including, without limitation, Acts of
God, strikes or other labor disputes, war, riot, earthquake, fire, civil disorder, explosion, accident, flood, sabotage, lack of or inability to obtain adequate fuel, power, materials, labor, containers, transportation, supplies or equipment,
compliance with governmental requests, laws, rules, regulations, orders or actions, national defense requirements, or supplier strike, lockout or injunction (a “Force Majeure Event”). Such excuse shall continue as long as the
Force Majeure Event continues, except that Nycomed shall have the right to (i) terminate the Agreement without further obligation in the event that POZEN is not able to supply Nycomed with Product for a continuous period of six (6) months and (ii)
seek an alternate supplier of the Product during the continuation of, and only during the continuation of, such a Force Majeure Event unless Nycomed can only secure an alternate supplier for a time period in excess of the Force Majeure Event period,
in which case Nycomed shall resume its exclusive supply relationship with POZEN at the end of such period and extend the Term by a maximum of six (6) months. A breakage or failure of machinery not arising as a result of DSM’s failure to
properly maintain such equipment in accordance with this Agreement shall also be considered a Force Majeure Event; however, in such case, the six (6) month period heretofore applied in this Section 18.1 shall be sixty (60) days. If no such
termination by Nycomed occurs, upon cessation of such Force Majeure Event, the Parties shall promptly resume performance hereunder. 
  
 18.2 Notice of Force Majeure Event. In the event either Party is delayed or rendered unable to perform due to a Force Majeure Event, the
affected Party shall give notice of the same and its expected duration to the other Party promptly after the occurrence of the cause relied upon, and upon the giving of such notice the obligations of the Party giving the notice shall be 

 

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 16 

 suspended during the continuance of the Force Majeure Event; provided, however, such Party shall take commercially
reasonable steps to remedy the Force Majeure Event with all reasonable dispatch. The requirement that Force Majeure Event be remedied with all reasonable dispatch shall not require the settlement of strikes or labor controversies by acceding to the
demands of the opposing party. 
  
 ARTICLE 19 
  
 LEGAL COMPLIANCE; AUTHORIZATION 
  
 19.1 Legal Compliance. Each Party shall comply in all material
respects with all federal and state laws and regulations applicable to the conduct of its business pursuant to this Agreement, including, but not limited to, the FD&C Act. 
  
 19.2 Authorization. 
  
 (a) POZEN hereby represents and warrants to Nycomed that all corporate action on the part of POZEN and its officers and directors necessary for the
authorization, execution and delivery of this Agreement and the performance of all obligations of POZEN hereunder has been taken. 
  
 (b) Nycomed hereby represents and warrants to POZEN that all requisite action on the part of Nycomed and its officers and directors necessary for
the authorization, execution and delivery of this Agreement and the performance of all obligations of Nycomed hereunder has been taken. 
  
 ARTICLE 20 
  
 DISPUTE RESOLUTION; VENUE 
  
 20.1 Exclusions. Section 20.2 below shall not apply to any disputes arising under Article 15 or Article 16 hereof. 
  
 20.2 Dispute Resolution. The Parties recognize that a bona fide dispute as to certain matters may from time to time arise during the Term which
relates to either Party’s rights and/or obligations hereunder. In the event of the occurrence of such a dispute, either Party may, by notice to the other Party, have such dispute referred to their respective officers designated below, or their
successors, for attempted resolution by good faith negotiations within thirty (30) days after such notice is received. Such designated officers are as follows: 
  

For Nycomed – Chief Executive Officer 
 For POZEN – President, Chief Executive Officer 
  
 In the event the
designated officers are not able to resolve such dispute within such thirty (30) day period, or such other period of time as the Parties may mutually agree in writing, each Party shall have the right to pursue any and all remedies available at law
or in equity. 
  
 20.3 Venue. Any court proceeding
initiated by one Party against the other Party with 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 17 

 respect to this Agreement shall be commenced in the courts of law located in Raleigh, North Carolina; provided, however,
if the court proceeding is brought as a third party action as part of a pending proceeding in a different venue, either Party may initiate such third party action against the other Party in such other venue. 
  
 ARTICLE 21 
  
 MISCELLANEOUS 
  
 21.1 Independent Contractors. The relationship between Nycomed and
POZEN is that of independent contractors and nothing herein shall be deemed to constitute the relationship of partners, joint venturers, nor of principal and agent between Nycomed and POZEN. Neither Party shall have any express or implied right or
authority to assume or create any obligations on behalf of or in the name of the other Party or to bind the other Party to any contract, agreement or undertaking with any Third Party. 
  
 21.2 Responsibilities and Assistance. To assist the Parties in their performance of this Agreement, each Party shall
provide the other Party, in a timely fashion, with all relevant information, documentation and data that is necessary or appropriate for each Party’s performance hereunder. Nycomed shall ensure that any and all materials supplied to DSM by or
on behalf of Nycomed, whether or not through POZEN, (a) are suitable for use under this Agreement, comply with all applicable laws and regulations (including without limitation those relating to the import of such materials), and (b) have
received all required governmental and regulatory approvals; provided, however, that in no event will this sentence be construed to modify the distribution of responsibilities of the Parties with respect to obtaining regulatory approval for the
Product in the Territory as set forth in the License Agreement. If a Party requests support or information from the other Party, the replying Party shall provide such support or information (or an explanation of the legitimate reason for any delay
and a projected date by which such support or information shall be provided) within five (5) business days of such request. In the event either Party is to review or approve any information, documentation, data or samples prepared or supplied by or
on behalf of the other Party, the replying Party shall complete such review and approval process within five (5) business days. Each Party shall cooperate with the other Party in the performance of this Agreement and shall deal honestly and in good
faith with the other Party. 
  
 21.3 Assignment;
Subcontractors. This Agreement may not be assigned or transferred by either Party without the prior written consent of the other Party, which consent shall not be unreasonably withheld; provided, however, either Party may, without such consent,
assign this Agreement (a) [***] (b) [***], or (c) [***]. Any purported assignment in violation of the above shall be void. Any permitted assignee shall assume all obligations of its assignor under this Agreement; provided, however,
that in the event of [***] by the foregoing clause 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 18 

 (b) [***]. No assignment shall relieve either Party of responsibility for the performance of any obligation which accrued
prior to the effective date of such assignment. At its option, POZEN may use subcontractors to perform any part of this Agreement; provided, however, that POZEN requires such subcontractors to enter a confidentiality agreement with POZEN and to be
subject to all quality and all other standards and obligations as may be imposed on POZEN under this Agreement; and provided, further, that POZEN [***] In no event will the foregoing sentence be construed to limit POZEN’s obligations under this
Agreement to [***]. 
  
 21.4 Continuing Obligations.
Termination, assignment or expiration of this Agreement shall not relieve either Party from full performance of any obligations incurred prior thereto. 
  
 21.5 Waiver. Neither Party’s waiver of any breach or failure to enforce any of the terms and conditions of this Agreement, at any time, shall
in any way affect, limit or waive such Party’s right thereafter to enforce and compel strict compliance with every term and condition of this Agreement. 
  
 21.6 Severability. Each Party hereby expressly agrees that it has no intention to violate any public policy, statutory or common laws, rules,
regulations, treaty or decision of any government agency or executive body thereof of any country or community or association of countries; that if any word, sentence, paragraph, clause or combination thereof in this Agreement is found by a court or
executive body with judicial powers having jurisdiction over this Agreement or either Party hereto, in a final unappealed order, to be in violation of any such provisions in any country or community or association of countries, such words,
sentences, paragraphs, clauses or combination shall be inoperative in such country or community or association of countries and the remainder of this Agreement shall remain binding upon the Parties, so long as enforcement of the remainder does not
violate the Parties’ overall intentions in this transaction. 
  
 21.7 Headings. The headings in this Agreement are for convenience of reference only and shall not affect its interpretation. 
  
 21.8 Exhibits, Schedules and Attachments. Any and all exhibits, schedules and attachments referred to herein form an integral part of this
Agreement and are incorporated into this Agreement by such reference. 
  
 21.9 Notices. All notices and other communications required or permitted to be given under this Agreement shall be in writing and shall be delivered personally or sent by (a) registered or certified mail, return receipt
requested, (b) a nationally-recognized courier service guaranteeing next-day delivery, charges prepaid or (c) facsimile (with the original promptly sent by any of the foregoing manners), and shall be deemed to have been given upon mailing or upon
transmission by facsimile, as the case may be. Any such notices shall be addressed to the 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 19 

 receiving Party at such Party’s address set forth below, or at such other address as may from time to time be
furnished by similar notice by either Party: 
  

			
	If to POZEN:	  	POZEN, Inc.
	 	  	1414 Raleigh Road
	 	  	Suite 400
	 	  	Chapel Hill, NC 27517
	 	  	Attention: President and Chief Executive Officer
	 	  	Telephone: (919) 913 1030
	 	  	Facsimile: (919) 913 1039
	
	With copies of legal notices to:
	 	  	Cooley Godward LLP
	 	  	One Freedom Square
	 	  	Reston Town Center
	 	  	11951 Freedom Drive
	 	  	Reston, VA 20190-5656
	 	  	Attention: Matthias Alder
	 	  	Facsimile: (703) 456-8100
		
	If to Nycomed:	  	Nycomed Danmark ApS
	 	  	Langebjerg 1
	 	  	DK-4000 Roskilde
	 	  	Denmark
	 	  	Attention: Managing Director Bent Kjærsgård
	 	  	Facsimile: +4546756968
		
	With copies to:	  	Nycomed Danmark ApS
	 	  	Langebjerg 1
	 	  	DK-4000 Roskilde
	 	  	Denmark
	 	  	Attention: General Counsel Theresa Comiskey Olsen
	 	  	Facsimile: +4766763513

  
 21.10
Counterparts. This Agreement and any amendment or supplement hereto may be executed in any number of counterparts and any Party hereto may execute any such counterpart, each of which when executed and delivered shall be deemed to be an original
and 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 20 

 all of which counterparts taken together shall constitute but one and the same instrument. The execution of this
Agreement and any such amendment or supplement by any Party hereto shall not become effective until counterparts hereof have been executed by both Parties hereto. 
  
 21.11 Governing Law; Entire Agreement. The validity, interpretation and performance of this Agreement shall be
governed and construed in accordance with the laws of the State of North Carolina without regard to the conflicts of laws provisions thereof that would cause the application of the laws of a different jurisdiction. This document constitutes
the full understanding of the Parties and a complete and exclusive statement of the terms of their agreement regarding the subject matter hereof. This Agreement shall not replace or supersede the License Agreement, but shall exist as a separate and
additional agreement between the Parties; notwithstanding the foregoing or anything to the contrary in this Agreement or in any other document or agreement, in the event of a conflict between this Agreement and the License Agreement, the License
Agreement shall govern and control. No terms, conditions, understanding, or agreement purporting to modify or vary the terms of this Agreement shall be binding unless hereafter made in writing and signed by the Party to be bound. No modification to
this Agreement shall be effected by the acknowledgment or acceptance of any purchase order or shipping instruction forms or similar documents containing terms or conditions at variance with or in addition to those set forth herein. 
  
 21.12 Construction. This Agreement was originally drafted by POZEN and
subsequently has been jointly prepared on the basis of the mutual understanding of the Parties and shall not be construed against either Party by reason of such Party’s being the drafter hereof or thereof. 
  
 [Remainder of page intentionally left blank. Signature page follows.]

  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 21 

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly
authorized representatives as of the day and year first above written. 
  

	
	POZEN Inc.
	

	
	 John R. Plachetka

	
	 President and Chief Executive Officer

	
	NYCOMED DANMARK APS
	

	
	 Håkan Björklund

	
	 Chief Executive Officer, Nycomed Group

	  

	
	 Bent Kjærsgård

	 Managing Director, Nycomed Danmark ApS

  
 [SIGNATURE PAGE TO THE SUPPLY AGREEMENT] 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 EXHIBIT 1 
  

PRODUCT PRICE 
  

					
	Product	 	Unit Price	 	Volumes (tablets)
			
	 [***]
	 	 	 	 
			
	 [***]
	 	 	 	 

  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 EXHIBIT 2 
  

SPECIFICATIONS 
  
 [***] [This and the following 9 pages have been redacted] 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00073-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00073-of-00352.parquet"}]]